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ABSTRACT 
 
Osteoporosis is a pathological condition characterized by a reduction in bone mass and 
modifications in bone microarchitecture, resulting in increased bone fragility and fracture risk. 
These fractures are widely recognized as a major health problem in the elderly population. 
Preliminary data reports that the bone regeneration process, in osteoporotic conditions, may 
be somewhat limited mainly due to a decrease of new bone formation. Nowadays, current 
bone tissue engineering strategies require biomodulators to achieve a successful regeneration 
of the bone tissue. Tetracyclines are suitable candidates for bone regenerative strategies 
because they have high affinity to mineralized tissues and an antibacterial action. 
This experimental work aims to establish two animal models, representative of the human 
osteopenic and osteoporotic conditions, and to assess the in vitro effect of doxycycline in the 
cellular behavior of grown osteoblastic cultures established from osteopenic and osteoporotic 
conditions. Briefly, rat bone marrow-derived osteoblastic cultures were established from three 
different experimental conditions – sham, osteopenic and osteoporotic animals – and grown in 
the presence of doxycycline, in order to depict its effect in cell proliferation, metabolic and 
functional activities. 
Cell cultures established from the sham group shown an increased cell proliferation in the 
presence of doxycycline. Doxycycline was also found to enhance metabolic activity and ALP 
expression of the established cultures. Cultures established from osteopenic animals revealed 
an increased cell proliferation that was stimulated in the presence of doxycycline. The 
expression of ALP was also improved with addition of doxycycline, being maintained the 
osteoblastic phenotype during the time of culture. In cultures established from osteoporotic 
animals, doxycycline delayed the cell proliferation and metabolic activity, so cell confluence 
was reached later. On the other hand, the ALP activity was enhanced by the addition of 
doxycycline. In cultures established from the three metabolic conditions, an enhanced 
expression of osteocalcin and osteopontin were also verified in the presence of doxycycline, as 
well as a reduction in some adipogenic markers. 
The results present in this study revealed that doxycycline can improve the osteogenic 
potential of osteoblast precursor cells in osteopenic and osteoporotic conditions. Therefore, 
these antimicrobial drugs can be useful in tissue engineering and have a potential biomedical 
application, being used in the management of osteoporosis and related conditions. 
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RESUMO 
 
A osteoporose é uma condição patológica caracterizada pela diminuição da massa óssea e 
alteração na arquitetura microscópica do osso, tendo como resultado um aumento da 
fragilidade óssea e do risco de fractura. Estas fracturas são reconhecidas como um importante 
problema de saúde na população mais idosa. Segundo dados prévios, o processo de 
regeneração óssea, em condições de osteoporose, pode ser limitado devido, principalmente, a 
uma diminuição na formação de novo osso. Atualmente, estratégias de engenharia de tecidos 
assentam na utilização de biomoduladores para que a regeneração do tecido ósseo seja 
alcançada com sucesso. As tetraciclinas são candidatos apropriados para estratégias de 
regeneração óssea devido à sua elevada afinidade para tecidos mineralizados e à sua ação 
antibacteriana. 
Este trabalho experimental tem como objetivo o estabelecimento de dois modelos animais 
representativos das condições de osteopenia e osteoporose humanas, e a avaliação in vitro do 
efeito da doxiciclina no metabolismo e atividade funcional de populações osteoblásticas 
derivadas de condições osteopénicas e osteoporóticas. Foram estabelecidas culturas 
osteoblásticas derivadas de medula óssea de rato em três condições experimentais diferentes 
– sham, osteopénica e osteoporótica – e foi avaliado o efeito da doxiciclina na proliferação e 
atividade funcional das referidas culturas. 
As culturas celulares estabelecidas a partir do grupo sham demonstraram um aumento na 
proliferação celular na presença de doxiciclina. A doxiciclina também revelou um aumento da 
atividade metabólica e da expressão de ALP nestas culturas. As culturas estabelecidas a partir 
de animais osteopénicos revelaram um aumento na proliferação celular que foi estimulada na 
presença de doxiciclina. A expressão de ALP também aumentou com a adição de doxiciclina, 
sendo assim mantido o fenótipo osteoblástico ao longo do tempo de cultura. Nas culturas 
estabelecidas a partir de animais osteoporóticos, a doxiciclina atrasou a proliferação celular e a 
atividade metabólica, levando a que a confluência celular fosse alcançada mais tarde. Por 
outro lado, a atividade da ALP foi estimulada com a adição de doxiciclina. Nas culturas 
estabelecidas a partir destas três condições metabólicas, verificou-se um aumento na 
expressão de osteocalcina e osteopontina na presença de doxiciclina, tal como uma redução 
de alguns marcadores adipogénicos. 
Os resultados apresentados neste estudo revelaram que a doxiciclina pode melhorar o 
potencial osteogénico de células precursoras de osteoblastos em condições de osteopenia e 
osteoporose. Deste modo, este medicamente antimicrobial pode ser útil na engenharia de 
x 
tecidos e tem potenciais aplicações biomédicas, podendo ser utilizado no tratamento da 
osteoporose e condições relacionadas. 
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BONE TISSUE 
 
BONE STRUCTURE 
 
Bone is a connective tissue considerable complex and important since it is responsible for 
strength and stiffness of the skeleton, ensuring the protection of soft tissues and organs (1). 
Bone is constantly remodeling (bone resorption and bone formation) (2) and has two main 
components: the extracellular bone matrix and bone cells (3). 
Due to its unique characteristics, its material composition and structural properties (4), 
bone tissue has various functions of extreme importance in the human body such as: 
o Movement and locomotion (3); 
o Support – shape the skeleton that serves to support muscle insertion (3); 
o Protection – protects internal tissues and organs (e.g.: the central nervous system 
(CNS), the brain and spinal canal, and bone marrow) (3); 
o Plasticity – must be flexible enough to be able to remodel in response to external 
forces, but should also be rigid and resilient to forces (4); 
o Maintenance of mineral homeostasis, serving as a reservoir for storing minerals – 
calcium and phosphate ions (3,5-7). The bone contains 99% of the body’s calcium and 
acts as a reserve of this ion; 
o Provides the proper environment for hematopoiesis within the bone marrow spaces 
(6,7). 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Structure of bone tissue in a long bone (8). 
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CLASSIFICATION 
 
Macroscopic Classification 
 
Bones can be classified regarding the form, being characterized in long, short and flattened 
bones (3,7). The first ones have greater length than width, and most of the bones of the upper 
and lower members are of this type; the second ones exhibit the length similar to the width; 
the last ones have a thin and flattened shape and are, as a rule, rounded (3,9). 
The long bone comprises three components: the diaphysis that corresponds to the bone’s 
body; the epiphysis are the edges of the bone; and the epiphyseal plate is composed of 
cartilage that ossified and becomes the epiphyseal line (3). 
 
 
Microscopic Classification 
 
At the microscopic level, the bone tissue can be classified as cortical or compact bone, with 
high density and rich in mineralized bone matrix, and trabecular or cancellous bone, 
constituted by small cavities surrounded by bone matrix (Figure 2) (3,10). These two types of 
bone are formed by a lamellar pattern, in which the collagen fibrils are placed in alternating 
directions (7). 
 
 
 
 
 
 
 
 
Figure 2 – Schematic representation of the bone tissue – cortical and trabecular bone (11) 
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The cortical bone is approximately 80% of the bone tissue existing in the body and is 
located in the diaphysis of long bones (1,10) and on the surface of the majority of bones 
(Figure 3). It is a dense bone due to the compaction of the collagen fibers (3). It’s organized in a 
Haversian system (Figure 4) (7) that consists of a central canal, the Haversian canal, which is 
surrounded by concentric bone, lamellae. Inside of these lamellae are the osteocytes within 
small spaces, lacunae (3,7). Inside are the blood vessels, which are responsible for osteocytes, 
nerves and connective tissue nutrition (7). 
The cortical bone has two surfaces, the endosteum and the periosteum (7). The 
periosteum is a membrane of connective tissue that covers the outer surface of the bone and 
has a high osteogenic potential (1,3). The endosteum has a similar structure and it’s located in 
the inner surface of long bones. It consists of a single cell layer, including osteoblasts, 
osteoclasts and osteochondral progenitor cells (3). These two membranes play an important 
role in the nutrition of bone tissue and contain the major cells of bone metabolism. Thereby, 
have a significant contribution to bone remodeling and regeneration processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Typical structure of a long bone. (a) Long bone components – epiphysis and diaphysis; (b) Epiphysis 
constitution – trabecular bone; (c) Diaphysis constitution – cortical bone (12). 
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The trabecular bone is located inside the cortical bone, in the epiphyses of long bones 
(Figure 3) (10). It forms a network of bone plates connected to each other, the trabeculae, and 
the space between these is filled with bone marrow and blood vessels (Figure 4) (3). 
Trabeculae ensure the skeleton elasticity and stability. This type of bone is continuously 
remodeling, while cortical bone has a much slower renewal (13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Structure of cortical and trabecular bone tissue (14). 
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BONE TISSUE FORMATION 
 
The formation of new bone occurs during growth and in fracture repair (15,16). During 
development, there are two mechanisms responsible for bone tissue formation – 
endochondral ossification and intramembranous ossification (3). 
Most of the bone tissue is formed by endochondral ossification (17), which takes place in 
the cartilage (3). Thus, it’s formed a cartilaginous matrix that precedes the bone tissue 
formation. The cartilaginous cells differentiate into osteoblasts that will invade and secrete 
bony matrix (Figure 5) (17). On the other hand, intramembranous ossification is the bone 
formation de novo and occurs in connective tissue membranes (3,17). This is a formation way 
that derives directly from the mature osteoblast differentiation from mesenchymal 
condensations (Figure 6). 
These two mechanisms cease when the adolescent growth is accomplished and mark a 
transition to adult bone remodeling once bone activity is concentrated on maintenance and 
repair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Schematic representation of the endochondral ossification process (18). 
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Figure 6 – Schematic representation of the intramembranous ossification process (19). 
 
In both processes, the initially formed tissue is characterized as primary or immature bone 
tissue, in which collagen fibers form clusters arranged in an irregularly shape and without a 
defined organization. This is a temporary tissue that will be gradually replaced by secondary or 
lamellar bone tissue, which has an ordered cell and matrix arrangement. 
 
  
JOANA PINHO 
8 
BONE CELLS 
 
Bone tissue possesses various cell types that have origin in two distinct lines (Figure 7): 
o Cells from osteoblastic lineage – osteoblasts, osteocytes and lining cells – derived from 
mesenchymal stem cells (MSC) (2,15,20,21); 
o Osteoclasts derived from bone marrow hematopoietic cells (2,17). 
 
The development and differentiation of osteoblasts and osteoclasts are controlled by 
growth factors and cytokines produced in the bone marrow microenvironment and by 
adhesion molecules which mediate cell-cell and cell-matrix interactions (2). 
 
 
 
Figure 7 – Bone cell formation originated from two distinct lines: cells derived from mesenchymal cells – 
osteoblastic lineage cells (osteoblasts, osteocytes and lining cells), and cells derived from bone marrow 
hematopoietic cells – osteoclasts (22). 
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Osteobastic Lineage Cells 
 
The osteoblast lineage cells are responsible for the bone tissue formation during 
embryonic development, growth, remodeling, fracture repair or any bone defect. The 
differentiation process starts with an osteoprogenitor and then there’s a progressive 
differentiation – pre-osteoblast, osteoblast and osteocyte (Figure 8). 
 
 
Figure 8 – Differentiation of osteoblasts and osteocytes. The pre-osteoblasts slowly differentiate from MSCs, in the 
bone marrow, to adopt an osteoblastic phenotype. As the osteoid will be mineralized by osteoblasts, these are 
deposited as osteocytes in lacunae (23) 
 
 
Osteoblasts are the cells responsible for the organic matrix formation – osteoid – and 
subsequent mineralization, the process of hydroxyapatite (HA) deposition (2). The formation of 
HA crystals and subsequent bone matrix mineralization occurs when the content of these 
vesicles is released by exocytosis (3). 
They have a cuboid shape, basophilic cytoplasm, are mononuclear cells and have a limited 
half-life period (about 3 months) that can result in three different targets: apoptosis; being 
engaged by the mineralized extracellular matrix (ECM) and become osteocytes, or differentiate 
into lining cells (24,25). Osteoblasts are arranged side by side on bone surfaces in a similar way 
to a simple epithelium and are capable of transdifferentiate into adipocytes, myoblasts, 
chondrocytes and osteoprogenitor cells under appropriate conditions (15,16). 
There are numerous transcription factors responsible for the commitment of pluripotent 
mesenchymal cells into the osteoblast cell lineage. Core-binding factor α1 (Cbfa1), Runx-2 and 
Osterix (Osx) are the most important (26). Cbfa1 is a transcription factor of the runt-domain 
gene family and plays a critical role in osteoblast differentiation (27). Runx-2 is also a runt-
domain gene and is involved in the production of bone matrix proteins (27). Osx is essential for 
osteoblast differentiation at an early stage but it also inhibits osteoblast differentiation at a 
later stage (27). 
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Osteoblasts play an important role in the bone formation process and in the control of 
bone remodeling. During bone formation, mature osteoblasts synthesize and secrete collagen I 
(Col I) and several non-collagen proteins such as osteocalcin (OC), osteopontin (OPN) and bone 
sialoprotein (27). Osteoblasts also synthesize insulin-like growth factor-I (IGF-I), interleukin-1 
(IL-1) and IL-6. IGF-I secreted from osteoblasts in the bone tissue has been demonstrated to be 
a potent chemotactic factor that might play a main role in the recruitment of osteoblasts 
during bone formation (27). Apart from IGF-I, IGF-II, transforming growth factor-β (TGF-β) and 
platelet-derived growth factor (PDGF) are other examples of external regulators of osteoblast 
function (28). 
These cells are responsible for the production of bone tissue specific proteins, cell 
adhesion proteins, bone growth factors, proteoglycans and for storing enzymes, calcium and 
phosphate ions in vesicles. 
 
The osteocytes are the most abundant cell type in bone – there are 10 times more 
osteocytes than osteoblasts and its half-life is about twenty years. They are considered the 
most mature osteoblastic cells and result from the process whereby the osteoblasts are 
surrounded by mineralized bone matrix and stop producing it (3). 
These cells are regularly spaced throughout the mineralized matrix and communicate with 
each other and with cells on the bone surface via multiple extensions of their plasma 
membrane that run along the canaliculi (2). Osteocytes are surrounded by an ECM forming 
spaces called lacunae, which are connected to each other through channels that are occupied 
by osteocytes extensions (2). 
The location of osteocytes makes them good candidates for mechanosensory cells able to 
detect the need for bone augmentation of the skeleton and the need for microdamage repair 
(2). 
There is a direct relationship between the amount of osteocytes and the bone formation 
process. By this mean, the higher bone formation, the greater the amount of trapped 
osteoblasts, so the number of formed osteocytes will increase. 
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The lining cells are inactive osteoblasts with dense nuclei and a more flattened shape, 
which lie on the bone tissue surface. These cells have less cytoplasmic organelles than 
osteoblasts and its biological function is not well defined: seems to be responsible for the 
removal of the osteoid thin layer that coats the surface bone, thus exposing the bone to bone 
resorption performed by osteoclasts, and take part in typical osteoblasts functions under 
appropriate activation (25). 
 
 
Osteoclastic Lineage Cells 
 
Osteoclasts are giant, mobile and multinucleated cells with abundant mitochondria, 
numerous lysosomes and free ribosomes (2). These cells have the same origin as monocytes 
and macrophages and a short half-life period of approximately 2 weeks (Figure 9). 
Osteoclasts are responsible for the bone destruction or resorption process, which occurs 
through the release of acidic substances that form an acid microenvironment to dissolve the 
bone tissue. This acidic environment is created by the action of an ATP-driven proton pump 
located in the ruffled border membrane (2). 
The receptor activator of nuclear factor κB ligand (RANKL) is an osteoclast differentiation 
factor that binds to the RANK receptor in osteoclasts. Osteoprotegerin (OPG) is a soluble 
tumour-necrosis factor receptor that inhibits osteoclast differentiation by interacting with 
RANKL (26,27). 
Osteoclasts have high amounts of a phosphohydrolase enzyme, tartrate-resistant acid 
phosphatase (TRAP), a characteristic that is commonly used for the detection of osteoclasts in 
bone specimens (2). These cells also participate in long-term maintenance of blood calcium 
homeostasis and are important in bone development and growth through the release of 
growth factors. 
 
 
 
 
 
Figure 9 – Osteoclast differentiation. Osteoclasts are multinucleated giant cells that differentiate from 
monocyte/macrophage lineage hematopoietic cells in the bone marrow (23). 
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BONE MATRIX 
 
The bone matrix is composed of two different components, an inorganic component (50-
70%) and an organic component (30-50%). The rest are lipids and water. 
The organic material consists mainly of collagen which confers resistance to the matrix – 
types I, III and V, where the most abundant is type I – and proteoglycans (1-3,17). There are 
also non-structural proteins, such as growth factors, blood proteins, osteonectin and OC (7). 
The inorganic material is responsible for the hardness of the bone matrix and is composed 
mostly by calcium (Ca2+) and phosphate (PO4
3-) ions that form crystals, also called HA crystals – 
Ca10(PO4)6(OH)2, when deposited in the matrix (1,3). These crystals are arranged along the 
collagen fibrils and are surrounded by proteoglycans and glycoproteins. Magnesium, sodium, 
potassium, bicarbonate and citrate ions also exist in the bone matrix but in lowest amount. 
The combination of HA with collagen fibrils gives the hardness and strength to the bone tissue 
that characterize it. 
Calcium is the main mineral in the skeleton formation, acting in its structure, internal 
organs protection and locomotion. Moreover, muscle contraction, blood clotting and neuronal 
excitation mechanisms require calcium (7,29). Thereby, the calcium concentration must be 
kept within specific limits in the different physiological compartments. 
The phosphate anion also exists in high concentration in bone tissue, being the major 
constituent of their crystalline structure. It is also an essential component of the membrane 
lipids and DNA, so it’s crucial for cell signaling (7). The balance and homeostasis of plasmatic 
phosphate are the reflection of food diet, renal excretion and internal exchanges between the 
extracellular fluid, soft tissues content and skeletal reservoirs (30). 
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BONE REMODELING 
 
The bone tissue is in constant remodeling, i.e. there is a continuous balance between 
resorption and formation of new bone (25,31,32), regulated by the action of osteoclasts and 
osteoblasts, respectively (1,2,5,15,33). Bone remodeling is a physiological process that 
maintains the skeleton integrity (34). Through this process, about 5% of cortical bone and 20% 
of trabecular bone is renewed per year (35). It can be said that it is the cellular basis of bone 
metabolism, thus a change in the process may lead into a metabolic disorder. 
 
 
 
 
 
 
 
 
 
Figure 10 – Bone remodeling process (36) 
 
At the microscopic level, the bone remodeling process takes place in small areas of the 
cortical and trabecular surface called basic multicellular units (BMUs), characterized by the 
coordinated action of osteoclasts and osteoblasts (2,27,35). BMUs are a unique temporary 
structure with about 6-9 months of lifespan. During this time numerous generations of 
osteoclasts (lifespan of about 2 weeks) and osteoblasts (lifespan of about 3 months) are 
formed. The BMU comprises a group of osteoclasts in the front, a group of osteoblasts in the 
rear, a central vascular capillary, a nerve supply and associated connective tissue (2). 
 
A bone remodeling cycle consists of four different and sequential phases – activation, 
resorption, reversal and formation. 
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Bone remodeling begins with the activation of resting cells to the resorption place, 
including osteoclastic precursors and bone-marrow mononuclear monocyte-macrophages, 
which differentiate into multinucleated cells and active resorbing osteoclasts that begin the 
resorption process (27). In these phase the osteoclasts begin to dissolve the mineral matrix 
and decompose the osteoid matrix. There is also the release of growth factors contained 
within the matrix, essentially TGF-β, PDGF, IGF-I and IGF-II (35). After the bone resorption, 
osteoclasts migrate from the resorption site that is then invaded by a heterogeneous 
population of mononuclear cells with macrophage and pre-osteoblastic cells. 
When resorption is completed, it starts the reversal phase where the osteoclasts die 
through apoptosis and osteoblast precursors locally proliferate, differentiate into mature 
osteoblasts and migrate into the resorption lacuna made by osteoclasts (27). 
The following stage is the formation phase, in which osteoblasts synthesize new osteoid 
material that fills the resorption lacuna and becomes mineralized in the resting phase (27,35). 
As the organic matrix is mineralized, it surrounds the osteoblasts, which lose their synthetic 
activity and are therefore called osteocytes. 
 
The activation and regulation of bone resorption requires an interaction between 
osteoblasts and osteoclasts. The molecular mechanism that supports this relationship is 
explained by the RANK/RANKL/OPG system (Figure 11). RANK is a protein member of the 
tumor necrosis factor (TNF)-receptor superfamily and is expressed by mature osteoclasts, 
dendritic cells and some cancer cells (27). RANKL is a TNF superfamily member expressed by 
osteoblasts and is essential for the recruitment, differentiation, activation and survival of 
osteoclastic cells through binding to its specific receptor RANK (27). OPG is a soluble receptor 
of RANK and is synthesized by osteoblasts, stromal cells, vascular smooth muscle cells, B 
lymphocytes and articular chondrocytes (27). 
By modulating RANKL and OPG, osteoblasts can control osteoclast differentiation and 
activity and consequently bone remodeling: RANKL binds to RANK that is present on the 
surface of osteoclast precursors leading to the activation of Nuclear Factor κB and 
transcription of genes involved in osteoclastogenesis. OPG has the ability to act as a decoy by 
binding to RANKL and blocking the RANKL/RANK interaction (2,27). This way, OPG inhibits 
osteoclastogenesis, osteoclast activity and bone resorption. 
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Figure 11 – Molecular mechanism of the RANK/RANKL/OPG system. 
 
Bone remodeling is a key process in the normal body behavior because it gives the 
characteristics that bone needs to maintain physiological functions (15). Furthermore, bone 
remodeling replaces old bone with inferior biomechanical properties and helps maintaining 
the normal calcium and phosphate concentrations (37). 
In young adults, the rate of bone resorption and formation are ideally equal, and the total 
bone mass remains constant, which do not occur in children, where bone formation rate is 
higher than bone resorption, since the bones are growing (7). 
Bone remodeling increases in premenopausal and postmenopausal women being then 
attenuated with age in both genders, continuing to be faster than in pre-menopausal periods 
(7,38). 
In pathological situations, it is common to see a change in the normal functioning of bone 
remodeling, i.e., an imbalance between the processes of bone formation and bone resorption, 
which leads to bone loss (39). Thus, there is an increase in the osteoclasts number and activity, 
the cells responsible for the bone resorption process, and/or a decreased differentiation of 
osteoblasts, which are responsible for bone formation (39). Osteoporosis is an example of a 
bone disease where this occurs. 
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BONE METABOLISM 
 
Bone is a mineral that releases calcium and phosphate in response to hormones secreted 
by several organs. These elements are very significant in the bone composition, and the levels 
monitoring are essential to the performance of many vital physiological functions. Therefore, 
normal levels of calcium, phosphate and related minerals are maintained by a complex 
regulatory system. The major hormones that regulate these values are the parathyroid 
hormone (PTH) and vitamin D (38). The calcitonin, growth hormone (GH) and estrogens also 
play an important role in the regulation of bone metabolism. 
 
The parathyroid hormone (PTH) is released by the parathyroid glands and its secretion is 
regulated by plasmatic concentration of calcium (13,29,40). The primary effect of PTH is to 
increase plasmatic calcium levels and reduce plasma phosphate concentration, acting in three 
main organs – the bone and the kidney, directly, and the gastrointestinal tract, indirectly 
(13,29,41). In the bone, PTH receptors are present in osteoblasts as well as in osteoclasts, and 
its effect in this tissue involves two mechanisms: 
o An immediate stimulation consists in the activation of the bone cells present in the 
bone tissue. PTH binds to specific receptors in osteoblasts and osteocytes and 
activates a calcium pump, where calcium is transferred from the bone fluid to the 
extracellular medium. Calcium levels in the bone fluid are rapidly replenished by 
removing calcium phosphate salts from amorphous deposits existent along the 
osteoblastic cells; 
o A slower effect, that can take several days or weeks, consists in the activation of 
the osteoclast system, with an increase in the osteoclasts recruitment and activity. 
This process will lead to an increased resorption of mineralized bone tissue. 
 
  
LITERATURE OVERVIEW 
17 
Vitamin D in its active form – 1.25-dihydroxyvitamin D3 (calcitriol) – is a steroid hormone 
(35) and one of the major regulators of calcium metabolism. Its main functions are to stimulate 
intestinal absorption of ingested calcium and to promote the calcium resorption by the bones 
(13,40). In the bone, only osteoblasts have calcitriol receptors, despite vitamin D stimulate 
bone resorption. As a result, recruitment, differentiation, and fusion of precursors into active 
osteoclast increase. Vitamin D is also involved in the process of new bone formation by 
inducing the synthesis of osteocalcin in osteoblasts. Moreover, it has an action of negative 
feedback suppressing, in a direct way, the gene responsible for the PTH synthesis (13,40). 
 
Calcitonin is produced in the parafollicular cells of the thyroid and its greater effect on 
bone metabolism is the reduction of plasma calcium concentration caused by the inhibition of 
bone resorption (28,35,41). By this way, it reduces the number and activity of osteoclasts (35). 
Hence, calcitonin is a physiological antagonist of PTH hormone in relation to calcium levels. 
However, their effect on phosphate concentration is similar, i.e. reduces plasma phosphate 
levels. The greatest stimulus for calcitonin secretion is the increase in plasma calcium (13,30), 
but vitamin D may also promote calcitonin levels by food intake, without increasing calcium 
concentration. 
 
Growth hormone (GH) is produced and stored in the acidophilic cells of the anterior lobe 
of pituitary and promotes bone growth. GH increases both bone resorption and bone 
formation processes (13,30). Its action on cell growth requires the formation of peptides 
known as somatomedins, also called insulin growth factors (IGFs). These mediate the 
responses of GH on cartilage, bone tissue, muscle, fat tissue and fibroblasts (13). To highlight 
the effect of IGF-I on bone metabolism as it increases chondrocytes and osteogenic cells 
proliferation and proteins deposition by these two cell types. It also stimulates chondrocytes 
conversion into osteogenic cells leading to bone tissue formation (13). 
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Estrogens are hormones synthesized by the ovaries and have an important role in 
maintaining bone mass in women. They promote bone tissue formation (13). When estrogen 
levels are reduced there is an increase in the intensity of bone remodeling (4), which causes an 
imbalance between osteoblastic and osteoclastic activities. So there is an increase in 
osteoclasts activity and a decrease in osteoblasts activity, which leads to the formation of 
resorption spaces that are not filled by immature bone. Estrogens bind to specific receptors in 
the cytoplasm of bone cells, which results in formation and release of soluble factors with 
autocrine and paracrine actions in both osteoblasts and osteoclasts. This will influence their 
recruitment, proliferation, differentiation and metabolic activity (4). 
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BONE REGENERATION 
 
Bone is a highly specialized and dynamic tissue that has the capacity of self-regeneration. 
During development and growth bone undergoes a modeling process in which it is removed 
from one site to a different one (2). The bone regeneration is a process that takes place 
throughout life to replace the old bone with new and it has special importance when a fracture 
occurs. This is more common in bone pathologies, or by trauma, osteonecrosis and tumors. A 
fracture is a break in a bone that is always accompanied with damage in the adjacent tissues 
(42). In cases of bone tissue loss it is necessary the immediate stimulation of new bone 
production. 
There are a number of events that follow a bone fracture. They usually start with the 
formation of a wound, followed by the healing and finally the repair process. 
 
The injury process begins with the stimulation of growth and differentiation factors which 
then activate localized pluripotent osteoprogenitor cells. These cells produce bone 
morphogenetic proteins (BMPs) that induce the migration of mesenchymal cells, which in turn 
proliferate and differentiate into bone-forming cells (42). 
Afterward, it starts a rapid inflammatory response resulting in tissue edema and 
chemotaxis through the release of cytokines and growth factors. Then follows the first phase 
of collagen repair that involves the deposition and formation of granulation tissue, which 
becomes a new and temporary weak tissue. This process ends with the second stage of 
collagen repair that results in extracellular matrix remodeling, localized angiogenesis and 
reproduction of full-strength tissue. Bone remodeling is initiated with both endochondral and 
intramembranous ossification which are stimulated by hypoxia and vascular disruption at the 
fracture site (17,42). 
The above coordinated processes result in the reconstruction of normal bone and 
restoration of a structural unit. However, these normal bone regenerative mechanisms 
breakdown during failure of optimal bone remodeling and repair, or in large bone fractures 
and defects. 
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In these cases, it is necessary to resort to Tissue Engineering: an interdisciplinary field that 
applies the principles of engineering and the life sciences to the development of biological 
substitutes that restore, maintain, or improve tissue function (43). This is a new field of 
research that suggests the regeneration of the tissue instead of its substitution (44) and it has 
gained special attention due to the lack of clinical treatments capable of restoring full 
functionality. For that the use of grafts for bone repair is a good option. 
The autologous graft (graft from the individuals themselves) is the clinical gold standard, 
but although effective, with no immunogenicity, superior grafting and minimal risk of disease 
transmission, it has a limited supply of viable donor tissue, there is the need of additional 
surgeries, increased risk of infection and donor site morbidity (45,46). Allograft (graft from 
another individual) bone is an alternative to autografts but it also has some disadvantages 
related to limited donor supply, disease transmission and inadequate physiologic and 
biomechanical responses (46). 
The biologic mechanisms that provide a basis for bone grafting are osteoconduction, 
osteoinduction and osteogenesis. This way, the bone graft material must be osteoconductive 
serving as a structure (scaffold) that allows cells to migrate and function within its limits (46); 
osteoinductive providing factors that stimulate the proliferation and differentiation of 
osteoprogenitor cells into osteoblasts that then begin the new bone formation (46); and 
osseointegrative being capable of integrate into the surrounding tissue (46). 
Thus, the superposition of two or more materials in order to completely achieve these 
characteristics is a logical strategy. In effect, the creation of composites is a biomimetic 
approach, as bone can be viewed as a composite of collagen, the principal organic component; 
HA, the inorganic mineral component; water; and small amounts of other organic phases. 
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OSTEOPOROSIS AND OSTEOPENIA 
 
Osteoporosis is a pathological condition characterized by reduced bone mineral density 
(BMD) and microarchitectural changes in bone tissue that result in bone fragility and increased 
risk of fracture (2,31,32,47). A pathological imbalance between bone resorption and bone 
formation during the remodeling process may be the cause of this disease (31,39,48,49). Its 
most obvious morphological characteristic is bone loss, which tends to be more evident in 
skeleton areas with a high content in trabecular bone (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Morphological difference between a bone in physiological conditions and an osteoporotic bone (50). 
 
 
There are two classic forms of osteoporosis, the primary or physiological osteoporosis and 
the secondary osteoporosis (32), that is caused by other associated conditions. The first one 
can be divided into two forms: 
o Postmenopausal osteoporosis – often identified in women aged over 50 years (47,51) 
and characterized by high bone resorption rate resulting in an accelerated and 
increased osteoclastic activity caused by estrogen deficiency (52); 
o Senile osteoporosis – affects individuals of both genders with ages over 70 and has a 
normal or slightly increased bone resorption, associated with a decrease in the 
osteoblast activity that leads to low bone formation (52,53). 
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As stated earlier, secondary osteoporosis can be caused by several diseases that lead to 
skeleton weakness like genetic disorders – osteogenesis imperfecta and osteoporosis-
pseudoglioma syndrom; endocrine disorders – Cushing's syndrome, hyperparathyroidism, 
hypothyroidism and hypogonadism, and inflammatory or nutritional disorders – rheumatoid 
arthritis, Crohn's disease and celiac disease (38,52). 
 
Several systemic and local factors, both in physiologic and in pathological conditions, can 
influence the rigorously coupled activity of osteoblasts and osteoclasts, determining an 
imbalance in bone remodeling in favor of resorptive activity (27). As previously described, the 
RANK/RANKL/OPG system represents the main regulatory factors of the remodeling process. 
Some studies have demonstrated that this system is involved in the pathogenesis of 
osteoporosis (54,55). 
The peak bone mass is reached at the age of young adults, but during the third or fourth 
decade in both genders, bone resorption begins to exceed bone deposition. This bone loss 
associated with age is a common biological phenomenon and generally occurs in areas with 
high content of trabecular bone, such as the spine and neck of the femur. Thus, these sites are 
more prone to fractures in patients with osteoporosis. However, the rate of bone loss in each 
remodeling cycle can be anticipated by postmenopausal status, with women being more 
vulnerable to this condition and consequent complications. 
 
Osteopenia is a condition where BMD is lower than normal and is broadly considered by 
clinicians to be a precursor to osteoporosis. Nonetheless, not every individual diagnosed with 
osteopenia will embrace the development to the pathological state of osteoporosis. As a 
convention, the osteopenic condition is defined when the bone density is set one standard 
deviation below that of an average 30-year-old white woman; while osteoporosis is defined 
when this value reaches 2.5 standard deviations or more below the reference standard (56). 
Despite the controversy regarding the definition and the clinical usefulness of osteopenia, 
since it is an abstract concept, without any bio-pathological basis, it is highly regarded by 
clinicians as a precursor state of osteoporosis. In fact, anti-resorptive treatment is broadly 
initiated in this state, aiming to delay the onset of osteoporosis (56). 
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EPIDEMIOLOGY 
 
Osteoporosis is a disease with serious interest and concern since there is a high 
predisposition to fractures that cause pain, disability and, in some cases, premature death 
(37,57). There are several types of osteoporotic fractures, the most common occur in the 
vertebrae, wrist, femoral neck, distal radius and hip, and its epidemiology varies with age, sex 
and geographic location (37,58). 
The epidemiology of osteoporotic fractures is based on some general principles: the 
majority of fractures is related to low bone mass levels; the risk of a fracture is higher in 
women than in men; the risk of a fracture increases with age; it’s more likely to experience a 
fracture in patients who have suffered fractures in the past; vertebral fractures are very 
common, causing pain and disability, and are difficult to identify; vertebral fractures, with or 
without symptoms, indicate high risk of future fractures; the hip fracture is considered the 
most important type of fracture; the fracture risk may be genetically determined; several risk 
factors are related to decrease of bone mass (37). 
 
Osteoporosis affects more than 200 million people worldwide (59) and reveals a high rate 
of both mortality and morbidity in Western countries like Asia, Latin America, Middle East and 
Africa. This is a disease that affects men and women, although the risk of an osteoporotic 
fracture occurs in women is 2-4 times higher than in men (48). It is estimated that about 13% 
of men and 40% of women aged over 50 will suffer an osteoporotic fracture during her life 
time. These values increase to 22% in men and 47% in women taking into account future 
mortality trends. 
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PATHOPHYSIOLOGY 
 
Under physiological conditions, in an adult there is a balance between bone formation by 
osteoblasts and bone resorption by osteoclasts, in a dynamic process of bone remodeling. 
Osteoporosis occurs when there is a disturbance in this process and the balance tends in favor 
of bone resorption. This is a multifactorial disease and any model for its pathogenesis has to 
recognize a number of different mechanisms (32), shown below. 
 
o Age-related changes – during aging, the rate of bone remodeling increases in both 
genders (32). The amount of bone resorbed is higher than bone formed (4), and in the 
tissue level, osteoblasts formation is impaired compared to osteoclasts action, due to 
the decrease in number and activity of osteoblastic cells. These osteoblasts related 
disorders may be caused by extrinsic mechanisms which are mediated by changes in 
bone microenvironment, such as changes in level of hormones and growth factors, and 
intrinsic mechanisms caused by cellular senescence of osteoblasts. As a result, the 
formation of cortical and trabecular bone undergoes a decrease with age. The several 
growth factors deposited in the ECM also tend to become less potent with time. 
However, while the synthesis of new bone decreases with aging, the activity of 
osteoclast-mediated resorption remains unchanged. 
 
o Hormonal influences – the reduction of estrogen levels is associated with menopause 
(13,32,49,51), with an annual fall of about 2% of cortical bone and 9% of trabecular 
bone. Thus, it is not surprising that about half of postmenopausal women suffer 
osteoporotic fractures, when compared with the number of men in the same age 
group. 
Bone loss is more common in early postmenopausal women since the suppression of 
estrogen leads to an increased bone remodeling rate (4), creating many focus of bone 
remodeling in the endosteum. This deficit in estrogen promotes osteoclast activity 
because probably suppresses its apoptosis (52). The effect of decreasing estrogen level 
may be in part attributed to increased production of cytokines – particularly IL-1 and 
TNF (52). In addition, estrogens regulate resorption by limiting the release of RANKL by 
osteoblasts. The loss of estrogens leads to a significant increase in the expression of 
RANKL, which in turn results in excessive formation and activity of osteoclasts. At the 
same time, the levels of OPG increase with age, and it is possible that this production 
increases as a homeostatic response to limit bone loss which occurs with an increase 
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of other factors of bone resorption. However, despite some osteoblastic activity occurs 
simultaneously, the anabolic response seems to be insufficient to maintain the pace 
since bone resorption by osteoclasts is so high. 
The increase of osteoclasts activity promotes bone erosion by the cells helping to 
trabecular penetration and rupture of bone architecture. At each remodeling site, the 
amount of bone resorbed is greater than the replaced bone, producing a negative 
balance in the BMU, which is the basis of bone loss. Moreover, the lack of estrogen 
increases the prevalence of apoptosis, which may impair the ability of osteocyte to 
repair damage and thus contribute to promoting bone fragility. The fast initial drop in 
BMD is the result of the increase in porosity of many BMUs and occurs due to the 
normal delay in the onset of bone formation and due to the slow filling within various 
resorption cavities. The deterioration of microarchitecture may reflect the intensity 
and duration of osteoclastic activity and the number of osteoclasts formed. 
The increased remodeling and the negative bone balance lead to bone loss, trabecular 
narrowing and connectivity loss, cortical erosion and porosity. Later, a greater quantity 
of mineralized interstitial bone, away from the surface remodeling, accumulates 
damage on a microscopic scale, while the most superficial bone is replaced by younger 
and less mineralized bone, reducing the hardness. The bone remodeling by periosteal 
apposition reduces compressive pressure by distributing loads over a larger area and 
retains, in part, the torsional force. Additionally, it can be impaired by abnormalities in 
the function of periosteal osteoblasts or osteocytes signaling. 
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o Lifestyle – studies have shown that alcohol intake is a risk factor for bone loss, but it 
was concluded that the weight, the use of estrogen and tobacco are also important 
predictors for bone health (38). It is not known whether the reduction in BMD found in 
alcoholics is mostly due to an inadequate food intake, a lack of physical exercise or a 
direct effect of alcohol (32,60) in the reduction of osteoblastic activity. However, the 
most common is being a combination of all of these factors. 
The tobacco is also associated with several risk factors for osteoporotic fracture, such 
as a reduction in bone mass peak, early menopause and thinness. Apparently, smoking 
reduces BMD by a mechanism independent of its effect on weight or estrogen 
metabolism and can act to reduce calcium absorption. 
Physical activity is also important because it is known that the mechanical forces 
stimulate bone remodeling. Consequently, a decrease in physical exercise increases 
bone loss. This reduction in physical activity in older individuals may also contribute to 
senile osteoporosis. As the magnitude of skeletal loading has greater influence on 
bone density than the number of charge cycles, the type of physical activity is 
important. Thus, resistance exercises such as weight training leads to a more effective 
increase in bone mass than endurance activities like jogging. 
 
o Genetic factors – several population and genetic variations play an important role in 
the peak bone mass and changes in BMD. For example, the peak bone mass is higher 
in men than in women and in African people when compared with Caucasian or Asian 
individuals (38,61). In fact, genetic changes allow us to explain the high percentage of 
BMD variation. Polymorphism in vitamin D receptor may be responsible for 
approximately 75% of the variation in the peak bone mass achieved in a given 
individual (61). Other genetic variables can influence the cellular uptake of calcium or 
PTH synthesis and thus affect biological related responses. 
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o Calcium nutritional state – the calcium absorption by food intake may determine the 
status of bone metabolism (38). In the world population is of particular relevance that 
most teenage girls have inadequate dietary intake of calcium in the period of fast bone 
growth. As a result, they do not achieve their peak bone mass that would be expected, 
being more susceptible to develop clinically significant osteoporosis at an early age 
(62). 
1.25-Dihydroxyvitamin D, the active form of vitamin D, have important physiological 
activities like calcium absorption in gastrointestinal tract, regulation of calcium 
manipulation in the kidney, regulation of homeostatic control of bone remodeling, and 
synthesis regulation of the parathyroid hormone. If there is an abnormality in vitamin 
D formation, metabolism or action may occur an increase of bone resorption and 
therefore a more rapid bone loss (38). Subclinical deficiencies of vitamin D have been 
found in osteoporotic women. Vitamin D can also directly influence muscle strength 
and dexterity. 
 
o Glucocorticoids – chronic glucocorticoid therapy is known as one of the major causes 
of osteoporosis. High doses of glucocorticoids and long exposure periods to 
corticosteroids inhibit osteoblast proliferation and activity and enhance osteoblast and 
osteocyte apoptosis. They also enhance bone resorption by increasing the RANKL 
expression and reducing the production of OPG (27). 
 
Overall, the mechanisms described above can be grouped into three categories: 
o Failure to achieve optimal peak bone mass and strength – largely determined by 
genetic background, but can also be affected by lifestyle; 
o Faster bone loss due to resorption; 
o Weakened response to bone formation during the remodeling process – which 
physiologically occurs shortly after achievement of peak bone mass, but can be greatly 
enhanced by pathological mechanisms. 
 
Osteoporosis can also develop in connection with several pathological conditions – 
secondary osteoporosis – as stated above. The causes which lead to this type of osteoporosis 
include effects caused by prolonged therapy with glucocorticoids that increase bone 
resorption and decrease their synthesis (63). 
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DIAGNOSIS 
 
Osteoporosis is difficult to diagnose because it remains asymptomatic until the occurrence 
of a fracture (38). In the past, it was often diagnosed in postmenopausal women and older 
men, based on radiological findings and in the presence of small fractures. Recently, it was 
established an inverse relationship between BMD and fracture risk, which allowed making the 
diagnosis based on BMD measurements that enable disease identification even before a 
fracture occurs (62,64). 
 
 
Radiography 
 
In old times, radiographs were used to evaluate the peripheral skeleton BMD, usually at 
metacarpals level. The metacarpal cortical thickness was thus used for many years for 
diagnosing and predicting the risk for osteoporosis. However, the sensitivity of this 
radiographic technique is poor (65), and metacarpal measurement results do not reflect the 
BMD at most important sites such as the hip and spine (61). 
Radiographic analysis reveals bone loss recognizable only when 25-30% of bone density is 
lost, when osteoporosis is considered being in a more developed state. Although there is a 
correlation between BMD in central and peripheral skeleton, the association is not strong 
enough to predict central BMD measurements from a given peripheral bone (61). Nowadays, 
the main role of radiography is the diagnosis of secondary fractures to osteoporosis. 
 
 
BMD Measurement 
 
Quantitative analysis of bone density can be performed by several methods, among which 
we highlight the Dual-Energy X-Ray Absorptiometry (DXA), Quantitative Computed 
Tomography (qCT) and Quantitative Ultrasound (QUS). 
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Dual-Energy X-Ray Absorptiometry (DXA) 
 
Dual-energy X-ray absorptiometry (DXA) is a very precise and accurate technique for 
assessing bone density at several skeletal sites (66), that determine the absorption of two 
beams of photons at two different energies (67). With this method it is possible to measure 
BMD (mass/area) in proximal femur and lumbar spine, as well as the mineral density 
throughout the body. However, it fails to differentiate between measurements of cortical and 
trabecular bone. 
This method allows the BMD measurement in the hip or in the spine, with greater accuracy 
than other methods (accuracy error: 0.5-2%). The scanning time is about 5 minutes at each 
spot and the radiation dose is low (68,69). Besides the evaluation of normal anatomical sites, it 
may be used to provide side views of vertebral morphometric evaluations to determine 
vertebral fractures and deformities. 
The results are reported as a density measurement in g/cm2 and T and Z scores. The T 
scores represent the number of standard deviations below the mean BMD value for young 
adults (20-30 years old) (66). This is used to make diagnosis of normal bone density and with 
osteoporosis, in postmenopausal women and in men from the age of 50. The Z scores 
represent the number of standard deviations above or below the mean BMD value for subjects 
of the same age (66). These values are rather used to assess bone loss in premenopausal 
women and men younger than 50 years old. 
The World Health Organization (WHO) (70) defines osteoporosis as a result of BMD 
evaluation of standard deviation of 2.5 or higher. The WHO continues to seek a new algorithm 
for defining the limits of osteoporosis treatment that includes other factors such as age. 
Osteopenia is an intermediate category of bone loss defined as a T-score between 1 and 2.5 
(71). It’s a physiological condition characterized by the decrease of BMD. 
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Quantitative Computed Tomography (qCT) 
 
Quantitative Computed Tomography (qCT), with appropriate software, allows determining 
the absorption of different calcified tissues so that areas of interest as the vertebral body can 
be studied. This technique has the capability of evaluating bone density in three dimensions 
(g/cm3) (66). qCT has the advantage of distinguish trabecular from cortical bone. In addition, it 
can provide details related to the bone structure, including width and density in specific sub 
regions of cortical bone (66). The high resolution CT enables the measurement of trabecular 
diameter, inter-trabecular spaces and can identify abnormal trabecular architecture. 
Recent developments of tridimensional CT (3D) allowed the evaluation of the 3D 
trabecular structure and could improve the ability to estimate biomechanical properties of the 
bone. Dual energy scanning (with twice the dose of radiation) can improve accuracy but the 
precision worsens. The radiation dose and the price are considerably higher than those of 
conventional qCT. 
 
 
Quantitative Ultrasound (QUS) 
 
Quantitative ultrasound (QUS) provides information regarding bone mass and structural 
organization of the bone. It assesses the speed of sound or the absorption pattern of different 
sound wavelengths designated attenuation of ultrasound bandwidth (66). The attenuation of 
ultrasonic signals during the passage through the bone may be measured by determining the 
reduction in signal amplitude of ultrasounds. 
The ultrasound instruments have theoretical advantages in relation to DXA because they 
do not need radiation, are portable and cheaper. However, currently, it is difficult to apply the 
ultrasound to the clinic due to the lack of specific diagnosis criteria and the need to use 
manifold instruments. Moreover, as there are technical differences between devices, the 
results cannot be extrapolated from one device to another (66). 
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PREVENTION AND TREATMENT 
 
Osteoporosis is a bone disease that affects a large number of people at ever earlier ages. 
Thereby, the main goal is to identify individuals at risk of developing osteoporosis and provide 
them a safe, effective and economical intervention to prevent appearance of this disease. 
However, the factors that contribute to the occurrence of osteoporosis are very 
heterogeneous and there are a large number of genetic parameters that are unknown, making 
it difficult to create a complete plan for its prevention and treatment (52). 
Peak bone mass and resulting BMD are important throughout the growth and aging, which 
means that must be paid special attention to procedures that can optimize the level of bone 
mass (52). Thus, the approaches used for treatment and prevention of osteoporosis focus on 
prevention of bone loss. This can be done by several mechanisms: 
o Increase of calcium levels to reduce bone loss – calcium and vitamin D supplements 
(29,37); 
o Decrease in osteoclasts action to suppress bone resorption through pharmacological 
treatments – calcium, biophosphates, estrogens or analogs and calcitonin (29,37); 
o Increase in osteoblasts action to promote bone formation – low doses of PTH and 
testosterone (29,37). 
 
Prevention of this disease is also related to lifestyle, so it is encouraged the practice of 
regular physical exercise that is beneficial to maintain bone mass and reduce fracture risk 
(29,37,52); the reduction in alcohol, salt, caffeine and tobacco consumption, and nutritional 
care, such as increased consumption of animal protein and adequate calcium intake that 
maintains bone mass (37,52). 
With use of continuous treatments, probably indefinitely, it is possible to decrease the risk 
of fracture or at least keep it down. This strategy can be changed with the emergence of 
agents that substantially increase bone mass and restore microscopic architecture of the bone 
(37). However, the treatment of osteoporosis is difficult, both theoretical and practical, and 
the efforts that imposed directly on prevention measures are continuous. 
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TETRACYCLINES 
 
Tetracyclines are broad-spectrum antibiotics which act at the ribosomal level and interfere 
with protein synthesis (72). They were first used in the treatment of acne in the early 1950s 
and more recently have been considered for the biologic management of distinct conditions 
ranging from inflammation, proteolysis, angiogenesis, apoptosis, metal chelation, ionophoresis 
and bone metabolism. At the present, are available three groups of tetracyclines – natural-
derived products, semisynthetic compounds, and chemically modified tetracyclines (CMTs) 
(72). Tetracyclines can act in several clinical conditions that include periodontitis, 
osteoporosis/osteopenia, rheumatoid arthritis, cancer invasion and metastasis, corneal 
ulceration, abdominal aortic aneurysms, inflammatory skin diseases and other immune-
inflammatory conditions (73). 
Upon administration, tetracyclines are widely distributed into the tissues and can also 
achieve the cerebrospinal fluid. Besides that, as they chelate with the calcium ions, they are 
concentrated at mineralized tissues, namely bone and teeth. 
 
Tetracyclines and their derivatives are responsible for several actions that are independent 
from their antibiotic activity. Many of the non-antimicrobial properties may be related with 
their capacity for divalent cation quelation (74). These drugs proved to be effective against a 
range of mediators of the inflammatory cascade. Several direct or indirect mechanisms have 
been proposed – suppression of neutrophilic migration and chemotaxis, inhibition of T cell 
activation and consequent inhibition of their proliferation, inhibition and increased 
degradation of nitric oxide syntheses and pro-inflammatory cytokines inhibition. Tetracyclines 
can modify the expression of these mediators which makes them attractive for therapeutic 
action. 
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The anti-inflammatory actions include the inhibition of matrix metalloproteinases (MMPs) 
(75). MMPs are extracellular enzymes that rely on the availability of two cations per molecule 
to fulfill their enzymatic activity (76). Some MMPs (MMP-1, MMP-8 and MMP-13) are known 
as collagenases due to their capacity to break down fibrillar collagens. Others (MMP-2 and 
MMP-9) are known as gelatinases and are responsible for the degradation of collagen type IV, 
which can be found in the basement membrane. The MMPs family plays a role in angiogenesis, 
the process of formation of new blood vessels from pre-existing ones. Recent studies have 
shown that collagenases and other MMPs may participate in the degradation of type I 
collagen, the main component of the bone organic matrix and in the destruction of other 
connective tissue constituents. Thus, preliminary in vivo research has shown that tetracyclines 
were able to inhibit bone loss through inhibition of osteoclast-mediated bone resorption, but 
also by enhancing osteoblast activity, up regulation of type I collagen expression and increased 
bone formation (77,78). 
Other important non-antimicrobial property of tetracyclines and related molecules is 
associated with their eventual antiapoptotic effect. Furthermore, the interaction between 
tetracyclines and the bone system is known for a long time. These agents have been used as 
diagnostic markers for a long time (79). 
Overall, tetracyclines have been shown to inhibit MMPs, retard proliferation, induce 
apoptosis, and impair mitochondrial function in various experimental settings (80). Since the 
mid-twentieth century, they have found application beyond their anti-microbial activity in both 
the clinic and biomedical research; therefore, several translational studies were performed to 
demonstrate the clinical validity of it. After some research approaches, it was developed a low 
dose therapeutic regimen of doxycycline that showed to be non-antimicrobial, effective and 
safe. In this therapeutic regimen, doxycycline was found to achieve peak plasma levels of 
around 1 μg/mL. Doxycycline is a semi-synthetic tetracycline and remains the preferred 
tetracycline agent for most indications (81). 
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RESEARCH HYPOTHESIS 
 
It was hypothesized that due to the known effects of osteopenia/osteoporosis in the bone 
tissue structure and metabolism, doxycycline, known to enhance osteoblast functionality in 
physiological conditions, could further assist on the improvement of the osteogenic activity in 
the established impaired conditions. 
 
 
OBJECTIVES 
 
1) To establish rat models representative of the human condition of osteopenia and 
osteoporosis; 
2) To establish and characterize bone marrow-derived osteoblastic cultures from sham 
(control), osteopenic and osteoporotic animals, in the absence of exogenous osteogenic 
stimuli; 
3) To address the effects of doxycycline in the proliferation and functional activity of 
established sham, osteopenic and osteoporotic-derived osteoblastic cultures. 
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MATERIALS 
 
All cell culture chemicals and supplies were acquired from Merck and Sigma Aldrich (St. 
Louis, MO) unless otherwise noted. All tissue culture flasks and plates were obtained from 
Corning (Corning, NY). Doxycycline was obtained from Sigma Aldrich. 
 
 
METHODS 
 
ANIMALS 
 
Animals and Experimental Groups 
 
This experimental study was performed under the authorization of Direção Geral de 
Alimentação e Veterinária and observed the technical standards of protection of experimental 
animals, according to the Portuguese (Decree No. 1005/92) and European (Directive 2010/63) 
legislations. 
Nine nulliparous female Wistar rats, aged six weeks, were purchased from a certified 
vendor (Charles River laboratories, Barcelona) and housed in plastic cages, in a monitored 
environment, throughout the study period. Animals were given standard diet (4RF24 GLP, 
Mucedola®, Italy) and water, ad libitum. After a quarantine period of two weeks, rats were 
randomly assigned and housed together, in one of three groups: ovariectomized (OVX), sham 
(SHAM) and aged (AGE). 
Ovariectomy was performed to mimic the human osteoporotic post-menopausal 
condition, while the osteopenic condition was established through the physiological evolution 
of the aging process. Methodological approach and specific time points for ovariectomy and 
animal euthanasia were carefully selected accordingly to established data from the literature 
(82). Available information supports a fast modification of bone parameters following 
ovariectomy – similar to those attained in human post-menopausal osteoporosis – and a 
slower process of bone modification with aging, similar to the one verified in osteopenic 
human adults (82). 
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Accordingly, animals of the OVX group were ovariectomized at 8 weeks of age and 
euthanized at 20 weeks of age. Animals from the SHAM and AGE groups were submitted to a 
sham surgical intervention at 8 weeks of age, in order to minimize the bias of the surgical 
intervention. Animals of the SHAM groups were euthanized at 20 weeks of age and animals of 
the AGE group, were euthanized at 48 weeks of age. A schematic representation of the 
experimental protocol is depicted in Figure 13 . 
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Figure 13 – Schematic representation of the experimental protocol. 
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Ovariectomy and Sham Surgical Procedure 
 
Animals assigned to the OVX group were anesthetized by an intraperitoneal (IP) 
injection of xylazine (10mg/kg) and ketamine (90mg/kg). The abdominal cavity was assessed by 
a small midline dorsal skin incision, which allowed the blunt dissection of the connective tissue 
between the skin and the muscular layer of abdominal wall. Following, the muscular layers 
were opened half way down the side of the animal. Ovaries were identified and following 
pulled out through the incision. Two ligatures were placed, with absorbable 4-0 sutures: one in 
the caudal end, between the ovary and the uterine horn, and the other one in the cranial end 
of the ovary. Ovaries were following safely cut off and uterine horns pushed back into the 
abdominal cavity. Following inspection for abdominal hemorrhage, the abdominal muscle 
tissue was sutured with absorbable 4-0 sutures. Finally, the skin was sutured and animals were 
administered tramadol (10mg/Kg) IP, for post-operative analgesia. 
The same procedure was performed to all animals assigned to the SHAM and AGE 
groups, with the exception of the placement of ligatures and ovaries removal. Along the 
experimental protocol the animal’s weight was recorded monthly. 
 
 
Assessment of the Bone Tissue Structure 
 
In order to evaluate bone morphometric parameters, harvested tibias were submitted 
to microtomographic analysis (μCT). This is a non-destructive technique that allows the 
visualization and morphometric evaluation of microtomographic sections. 
Proximal tibia sections were digitized with an X-ray source of 50 Kv and an intensity of 
150 A, with a voxel size of 12 m. For each sample, a volume-of-interest (VOI) was defined 
within the trabecular component of the proximal tibia. VOI was delimited, 1 mm away from 
the growth plate, and with a 2 mm length on the metaphysis-diaphysis direction. 600 sections 
were acquired in each region. 
The following variables were calculated: 
o BV/TV: fraction of a given volume of interest (VOI, i.e. the Total Volume, TV) that is oc-
cupied by mineralized bone (Bone Volume, BV), expressed as %; 
o Tb N: trabecular number, expressed as 1/mm; 
o Tb Th: trabecular thickness, expressed as mm; 
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o Tb Sp: trabecular separation (or medular thickness), expressed as mm; 
o Mean Density: mean voxel values of tissue within BV, expressed as units of HA density. 
Different variables were calculated according to the methodological approaches 
described in the literature (83-85). 
 
 
ESTABLISHMENT OF THE BONE-MARROW DERIVED OSTEOBLASTIC CULTURES 
 
Cell cultures were obtained from bone marrow precursor cells of rat (rattus norvegicus) 
from Wistar rats, of the previously defined experimental groups. Animals were euthanized and 
preceded to the removal of their long bones from lower limbs – femurs and tibias – which 
were then placed in a decontamination solution: α-Minimal Essential Medium (α-MEM) 
supplemented with 25 µg/mL of fungizone (FUNGI) and 1000 IU/mL-1000 IU/mL of penicillin-
streptomycin (PEST). After 20 minutes in this solution, bones were transferred to another 
solution with the same composition for another 20 minutes. 
Once this time, epiphysis of all bones were removed and bone marrow cells were 
collected through perfusion of the spinal canal with culture medium: α-MEM supplemented 
with 10% fetal bovine serum (FBS), 2.5 µg/mL of FUNGI, 100 IU/mL-100 IU/ml of PEST and 50 
µg/mL of ascorbic acid (AA). The obtained cell suspension was seeded in 6-well plates with 9.5 
cm2 area at a temperature of 37°C in a humidified atmosphere of 95% air and 5% CO2 
(incubation stove with controlled atmosphere). After 7 days, the medium was changed to 
remove the non-adherent cells and then replaced twice weekly. Cultures were regularly 
observed by phase contrast microscopy. 
Cultures were maintained up to a confluence of approximately 80% – 15 days of culture. 
At this day cells were enzymatically released by trypsinization (trypsin 0.04%). Cells in 
suspension were counted in a hematocitometer (Nihon Kohden, MEK-5103K) and seeded at a 
density of 2x104 cells per square cm in 96-well plates (0.32 cm2 area). At adequate 
experimental settings, cultures were grown in the presence of doxycycline 1μg.ml-1. The 
culture medium was replaced twice weekly. Cells were maintained this way for 14 days. 
 
Cell cultures were characterized for viability, proliferation and differentiation event. 
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CHARACTERIZATION OF CELL CULTURES 
 
Cultures characterization – morphology, proliferation, viability and cell activity – was 
conducted through observation by optical microscopy and by histochemical and biochemical 
methods. 
 
 
Optical Microscopy 
 
Cell cultures monitoring was conducted periodically using phase contrast optical 
microscopy for the evaluation of cell morphology and proliferation. 
 
 
Cell Proliferation Assay (DNA Content) 
 
Cell proliferation was estimated by the DNA content at specific time points. DNA content 
was analysed by the PicoGreen DNA quantiﬁcation assay (Quant-iT™ PicoGreen® dsDNA Assay 
Kit, Molecular Probes Inc., Eugene), according to manufacturer’s instructions. Cultures were 
treated with Triton X-100 (0.1%) (Sigma) and fluorescence was measured on an Elisa reader 
(Synergy HT, Biotek) at wavelengths of 480 and 520 nm, excitation and emission respectively, 
and corrected for ﬂuorescence of reagent blanks. The amount of DNA was calculated by 
extrapolating a standard curve obtained by running the assay with the given DNA standard. 
 
 
Metabolic Activity Assay (MTT Assay) 
 
Metabolic activity of the cells was assessed by the MTT assay (86,87), which is based on 
the reduction of tetrazolium salt, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) 
by viable or metabolically active cells. As a result, it occurs the formation of purple crystals, 
designated formazan crystals. Following, the spectophotometric determination of the colored 
product is conducted. 
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The MTT analysis was performed at specific time points. On the selected day a MTT 
solution (5mg/ml) was added to each culture well and the cells were incubated for 4 hours in 
the conditions used during cell culture (37°C, humidified atmosphere of 95% air and 5% CO2). 
After the incubation period, culture medium was removed, dimethylsulphoxide (DMSO) was 
added to each well and plates were shaken to dissolve the formazan crystals. The absorbance 
was measured in an ELISA reader (Biotek, model Synergy HT) at 550nm. 
 
 
Apoptosis Assay 
 
Apoptosis was estimated by the Caspase-3 activity at specific time points. Caspase-3 
activity was analysed by the Caspase-3 assay (EnzChek® Caspase-3 Assay Kit #2), according to 
manufacturer’s instructions. Cultures were treated with Triton X-100 (0.1%) (Sigma) to obtain 
cell lysates and following, Caspase-3 activity was evaluated by fluorescence on an Elisa reader 
(Synergy HT, Biotek) at wavelengths of 480 and 520 nm, excitation and emission respectively, 
and corrected for ﬂuorescence of reagent blanks. The amount of reduced substrate was 
calculated by extrapolating a standard curve obtained from Rhodamine 110 reference 
standard. 
 
 
Assessment of Cell Morphology 
 
Cell cultures morphology was characterized by confocal laser scanning microscopy 
(CLSM) following staining of cytoskeleton and nucleus counterstaining. For CLSM assessment, 
cell cultures were fixed in 3.7% paraformaldehyde during 15 minutes and permeabilized with 
Triton X-100 (0.1%). Then cells were incubated with albumin (10 mg.ml-1) to reduce non-
specific staining. Cell cytoskeleton filamentous actin (F-actin) was visualized treating the cells 
with Alexa Fluor 488®-conjugated phalloidin (1:20 dilution in PBS for 20 minutes) and 
counterstained with propidium iodide (1 μg.ml-1 for 10 min) for cell nuclei labeling. Labeled 
cultures were mounted in Vectashield® and examined with a Leica SP2 AOBS (Leica 
Microsystems) microscopy. 
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Total Protein Content 
 
The total protein content was determined using the Lowry method (88,89). This is based 
on the reaction of Folin-Ciocalteau reagent with aromatic amino acids, and there’s the 
formation of a colored product, which is measured by spectrophotometry. 
After removing the culture medium, cells were washed twice with PBS buffer 
("Dulbeco's Phosphate Buffered Saline," Sigma D-1480), pH 7.4. It was added 100µL of Triton 
X-100 (0.1%) to each well and plates were placed in an incubator at 37°C for one hour. Once 
this time, samples were collected into eppendorf tubes, make up to volume of 300μl with 
NaOH 0.1 M and added to each sample 1.5 ml of an alkaline solution of copper. Allowed to act 
for 10 minutes, phenol reagent was added and the plate was placed in the dark for one hour. 
Once this time, absorbance was read in a spectrophotometer (Jenway, model 6300) at 750nm. 
Absorbance was compared with values obtained for a serie of standards of bovine serum 
albumin, made from a solution of 0.5 mg/mL in NaOH 0.1. 
Results were expressed in µg of total protein in the sample per square centimeter 
(µg/cm2). 
 
 
Alkaline Phosphatase Activity 
 
The alkaline phosphatase (ALP) activity was assessed by spectrophotometric 
determinination of the product obtained by hydrolysis of p-nitrophenylphosphate disodium 
(pNPP), upon reaction with ALP (p-nitrophenol). 
The culture medium was removed and cells were washed twice with PBS buffer, pH 7.4. 
It was added 100µL of Triton X-100 (0.1%) to each well to induce cell lysis. Thereafter, the 
substrate was prepared, 80μl were placed in each well and plate was incubated at 37°C for 30 
minutes. 
Results were expressed as nanomoles of p-nitrophenol produced per minute per 
microgram of protein (nmol/min.μg protein) as compared with respective calibration straight 
line. 
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Histochemical Methods 
 
Cell cultures were fixed at specific time points for further performance of histochemical 
techniques. The culture medium was removed and cells were washed with PBS at 37°C, pH 7.4. 
Cells were fixed with glutaraldehyde 1.5% for ten minutes. Thereafter, was added sodium 
cacodylate buffer at 0.14 M and samples were preserved at 4°C. 
 
 
Alkaline Phosphatase Staining 
 
Cell cultures were stained immunohistochemically to identify ALP activity by a method 
based on the hydrolysis of sodium naphthyl phosphate by ALP, and precipitation of phosphate 
liberated by reaction with a diazonium salt (Fast Blue RR). Hence, originates a colored product 
that, depending on amount of enzyme, may be yellow, brown or black. 
Cultures were placed in the dark for one hour, after fixation with buffer Tris 0.1 M, pH 
10, with 2 mg/ml of sodium naphthyl phosphate and 2 mg/ml of Fast Blue RR. After the 
incubation, samples were washed with distilled water and allowed to dry under ambient 
conditions. 
Cultures were photographed in a Nikon TMS Inverted Phase Contrast microscope with 
magnifications of 40x and 100x. 
 
 
Collagen Staining 
 
Collagen assay is based on the binding of a dye Sirius red F3BA (BDH, UK) – with the 
triple helical collagen fibril. 
The staining of the fixed cells was performed with 0.1% siriusred F3BA in saturated picric 
acid at room temperature, during 1 hour, under mild shaking. Afterward, the dye solution was 
removed by suction and the stained cell layers intensively washed with 0.01 N hydrochloric 
acid to remove all non-bound dye. 
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Gene Expression Analysis 
 
RT-PCR analysis was done in the three established cultures at specific time points. These 
were evaluated for the expression of ALP, bone morphogenic protein-2 (BMP-2), Col I, OPN, 
OC, OPG, PPARγ, CFD and AP-2. Total RNA was extracted using the NucleoSpin® RNA II Kit 
(Macherey-Nagel) according to the manufacturer’s instructions. The concentration and purity 
of total RNA in each sample were assessed by UV spectrophotometry at 260 nm and by 
calculating the A260nm/A280nm ratio, respectively. RT-PCR was done using the Titan One 
Tube RT-PCR system (Roche® Applied Science), according to the manufacturer’s instructions, 
for 28 cycles. RT reaction mixtures consisted of extracted RNA, Titan RT-PCR buffer, 
dithiothreitol (DTT), deoxynucleoside triphosphate (dNTP), primers for each tested gene, avian 
myeloblastosis virus RT (AMV-RT) and water, in a total volume of 25 μl. Total RNA was reverse 
transcribed with cDNA (30 minutes at 50ºC), which was then amplified with recombinant Taq-
DNA polymerase at different annealing temperatures. For all the genes, the annealing 
temperature was 60ºC. The PCR products were electrophoresed in a 1% agarose gel, stained 
with ethidium bromide and semi-quantitatively assessed by densitometry with Image J® 
software. 
 
 
STATISTICAL ANALYSIS 
 
Data presented in this work are the result of three separate experiments performed in 
cell cultures established from different animals. For biochemical data (MTT assay, total protein 
content and ALP activity) each point represents the mean ± standard error of 6 independent 
assays. Statistical analysis was done by one-way analysis of variance (ANOVA). P values ≤ 0.05 
were considered significant. 
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ASSESSMENT OF THE BONE TISSUE STRUCTURE 
 
The bone morphometric parameters were assessed by μCT analysis and the results are 
in Table 1. The BV/TV and Tb N values decreased in the osteopenic group and were even lower 
in osteoporotic group. The Tb Th and Tb Sp were found not to differ significantly between 
groups despite that Mean Density was significant reduced in osteopenic and osteoporotic 
groups, as comparing to sham. 
 
Table 1 – μCT values from Sham, Osteopenic and Osteoporotic groups. 
* – significantly different from control (p< 0.05). 
 
 
 
ESTABLISHMENT OF BONE MARROW-DERIVED OSTEOBLASTIC CULTURES 
FROM SHAM (CONTROL) ANIMALS 
 
In the first part of this study, the principal aim was to establish a bone marrow-derived 
osteoblastic culture from sham animals in two different conditions – in the absence and in the 
presence of doxycycline at 1 μg/ml. Cultures established in the absence of doxycycline were 
referred as ‘Control’; and cultures grown with doxycycline were termed as ‘D1’. 
Cells were cultured in control medium and the first subcultures were evaluated for cell 
morphology, cell viability/proliferation and osteoblastic differentiation throughout the 14 days 
of culture time. 
 
 
  
  Sham Osteopenic  Osteoporotic 
BV/TV (%) 54.33 ± 6.3 42 ± 4.78 * 17.78 ± 3.6 * 
Tb N (1/mm) 6.073 ± 0.54 5.329 ± 0.68 * 1.892 ± 0.41 * 
Tb Th (mm) 0.0897 ± 0.012 0.1065 ± 0.009 0.0917 ± 0.008 
Tb Sp (mm) 0.0998 ± 0.018 0.1278 ± 0.012 0.5452 + 0.014 
Mean Density (mg 
HA/ccm) 
883.5004 ± 57.302 846.3288 ± 32.795 * 836.1752 ± 44.784 * 
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CELL PROLIFERATION 
 
Graphic 1 shows the results of cell proliferation that was assessed by the DNA content. 
Control cell culture established from sham animals increased the proliferation rate during the 
time of culture. The culture with doxycycline had a similar behavior – increase in cell 
proliferation from day 5 to day 14 of culture. The addition of doxycycline revealed higher 
values in the proliferation rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METABOLIC ACTIVITY 
 
Metabolic activity was evaluated by the MTT assay (Graphic 2). Cultures established 
from sham animals presented an increase in MTT reduction values till day 10 and suffered a 
decrease of almost 50% at day 14. The cultures with doxycycline showed a similar behavior – 
MTT values increased from day 5 to day 10 and decreased at day 14. The metabolic activity in 
the culture with doxycycline is slightly higher than the one in the control culture in the first 
days of culture, but this pattern is reverted in the last days of culture. 
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Graphic 1 – Cell proliferation of sham rat bone marrow-derived cell cultures, established for 14 
days, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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APOPTOSIS 
 
Apoptosis was assessed by the Caspase-3 assay and is represented in Graphic 3. The 
apoptosis is broadly constant during the time of culture. The values between the control 
culture and the one with doxycycline are very similar with no significant differences between 
experimental conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Graphic 2 – Metabolic activity of sham rat bone marrow-derived cell cultures, 
established for 14 days, in the absence and in the presence of doxycycline. 
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Graphic 3 – Apoptosis of sham rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
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CELL MORPHOLOGY 
 
CLSM was the method used for the assessment of cell morphology and the acquired 
images are shown in Figure 14. At day 8, cells of the control culture exhibited expanded 
cytoplasm and an adequate nuclear organization. Besides that, several cell to cell contact were 
established. The cells proliferated adequately and, at this time point, a large area of the 
culture surface was already covered by cells. The cellular behavior of cultures with doxyxycline 
was similar. 
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Figure 14 – CLSM imaging of sham rat bone marrow-derived cell cultures, established for 14 days, in the absence 
and in the presence of doxycycline. 
Cytoskeleton was stained in green and nucleus counterstained in red. A to C corresponds to control cultures, and D 
to F corresponds to cultures with doxycycline. Magnification 400x. 
 
 
  
A B C 
F E D 
JOANA PINHO 
52 
ALKALINE PHOSPHATASE ACTIVITY 
 
Results of ALP activity were normalized by total protein content and are show in Graphic 
4. In the culture established from sham animals, alkaline phosphatase activity increased from 
day 5 to day 10 and suffered a decrease at day 14. The culture established in the presence of 
doxycycline showed a similar behavior – increased in the first days of culture and decreased at 
day 14. Comparing the two cultures, the ALP activity is higher in doxycycline culture at eighth 
and tenth days of culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALKALINE PHOSPHATASE STAINIG 
 
Representative figures of ALP staining are shown in Figure 15. Both control and 
doxycycline cultures presented a similar behavior concerning the production and distribution 
of ALP. Grown cells show a homogeneous ALP staining at day 5, in which the first cell clusters 
are detectable. This organization is easier identified at days 8 and 10, in which aggregates of 
cells have a more intensive staining – dark brown/black staining. This demonstrates an 
increase in ALP activity over time culture. 
 
 
Graphic 4 – ALP activity of sham rat bone marrow-derived cell cultures, established 
for 14 days, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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Figure 15 – ALP staining of sham rat bone marrow-derived cell cultures, established for 14 days, in the absence and 
in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
COLLAGEN STAINING 
 
Figure 16 shows representative images of collagen staining in cultures established from 
sham animals. In control culture is evident the formation of nodular structures since day 5 of 
culture which increased till day 14. Both cultures revealed an increase in the color staining in 
later time points, days 11 and 14. 
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Figure 16 – Collagen staining of sham rat bone marrow-derived cell cultures, established for 14 days, in the absence 
and in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
EXPRESSION OF OSTEOGENIC-RELATED MARKERS 
 
RT-PCR analysis showed that both experimental conditions – sham control cultures and 
with doxycycline – expressed high levels of significant osteogenic markers. Results are shown 
in Graphic 5. 
At day 7, control cultures expressed similar levels of ALP, BMP-2, Col I, OPG and OPN, 
while the levels of OC were lower. Cultures with doxycycline at this time point expressed 
higher levels of all of these markers except Col I that showed reduced values. At day 14, the 
expression of BMP-2, Col I and OPG slightly increased. On the other hand, the expression levels 
of OPN and OC decreased. In general, cultures with doxycycline at day 14 increased the 
expression of osteogenic markers. 
  
A B C D 
E F G H 
RESULTS 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXPRESSION OF ADIPOGENIC-RELATED MARKERS 
 
RT-PCR analysis of adipogenic markers in cultures established from sham animals is 
shown in Graphic 6. 
At day 7, the expression levels of AP-2 decreased in cultures with doxycycline. Also in 
the presence of doxycycline, CFD and AP-2 expression decreased, at day 14. 
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Graphic 5 – RT-PCR gene expression of ALP, BMP-2, Col I, OPG,OPN and OC, in sham rat bone marrow-derived cell 
cultures established at days 7 and 14, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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ESTABLISHMENT OF BONE MARROW-DERIVED OSTEOBLASTIC CULTURES 
FROM OSTEOPENIC ANIMALS 
 
In the second part of this study, the principal aim was to establish a bone marrow-
derived osteoblastic culture from osteopenic animals in two different conditions – in the 
absence and in the presence of doxycycline at 1 μg/ml. Cultures established in the absence of 
doxycycline were referred as ‘C osteopenic’; and cultures with doxycycline were termed as ‘D1 
osteopenic’. 
Cells were cultured in control medium and the first subcultures were evaluated for cell 
morphology, cell viability/proliferation and osteoblastic differentiation throughout the 14 days 
of culture time. 
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Graphic 6 – RT-PCR gene expression of PPARγ, CFD and AP-2, in sham rat bone marrow-derived cell cultures 
established at days 7 and 14, in the absence and in the presence of doxycycline 
 * – significantly different from control (p< 0.05). 
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CELL PROLIFERATION 
 
Cell proliferation was assessed by the DNA content and the results are in Graphic 7. 
Control cell culture from osteopenic animals showed an increasing proliferation throughout 
the culture time. In the culture with doxycycline, cell proliferation started with a lower value 
that is enhanced in almost 50% at day 8. Cell proliferation continued to increase and reached 
the highest value at day 14. 
 
 
 
 
 
 
 
 
 
 
 
 
Graphic 7 – Cell proliferation of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
 
 
METABOLIC ACTIVITY 
 
Metabolic activity was evaluated by the MTT assay (Graphic 8). Cultures established 
from osteopenic animals without introduction of any osteogenic inducers presented an 
increasing until day 10 and then suffered a slight decline. Cultures with doxycycline had a 
similar behavior – the MTT value increased from the first day of culture till day 10 and then 
decreased at day 14. The MTT reduction values were similar between the two experimental 
conditions. 
  
0
20
40
60
80
100
120
140
160
5 8 10 14
D
N
A
 (
n
g/
m
l)
 
Days 
C osteopenic
D1 osteopenic
JOANA PINHO 
58 
 
 
 
 
 
 
APOPTOSIS 
 
Apoptosis was assessed by the Caspase-3 assay and is represented in Graphic 9. The 
apoptosis levels were kept broadly constant throughout the culture period. The values of 
apoptosis were similar in the two experimental conditions. 
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Graphic 8 – Metabolic activity of osteopenic rat bone marrow-derived cell cultures, established 
for 14 days, in the absence and in the presence of doxycycline. 
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Graphic 9 – Apoptosis of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the absence 
and in the presence of doxycycline. 
 
 
CELL MORPHOLOGY 
 
CLSM was the method used for the assessment of cell morphology and the acquired 
images are shown in Figure 17. At early time points cells reported a characteristic osteoblastic 
morphology and evident cell to cell contacts. Cells proliferated actively and attended cell 
multilayer organization at later time points. No significant differences were found in cell 
morphology in control cultures and cultures with doxycycline. 
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Figure 17 – CLSM imaging of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
Cytoskeleton was stained in green and nucleus counterstained in red. A to C corresponds to control cultures, and D 
to F corresponds to cultures with doxycycline. Magnification 400x. 
 
 
ALKALINE PHOSPHATASE ACTIVITY 
 
Results of ALP activity were normalized by total protein content and are show in Graphic 
10. In the control culture established from osteopenic animals, ALP activity showed an increase 
over the time of culture. The culture established in the presence of doxycycline demonstrates 
a similar behavior, increasing the ALP activity from the first day till the last day of culture. 
Comparing the two experimental conditions, the ALP activity in the culture with doxycycline 
was significantly higher since the eighth day of culture. 
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Graphic 10 – ALP activity of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
 
 
ALKALINE PHOSPHATASE STAINIG 
 
Representative images of ALP staining are shown in Figure 18. It was verified an 
increased intensity for the two experimental conditions throughout the culture time. In both 
conditions the nodular aggregates were already visible at day 5 and increased over time, 
covering the vast majority of the culture. In later time points, the staining increased acquiring a 
dark brown/black staining, which is detectable in both conditions. This is in agreement with 
the ALP activity values showed above. 
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Figure 18 – ALP staining of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
COLLAGEN STAINING 
 
Representative images of collagen staining in osteopenic cultures with and without 
doxycycline are shown in Figure 19. In both conditions it’s verified the formation of nodular 
structures that increased over the time culture. The intensity of the staining also increases and 
in later time points, days 11 and 14, the pink is more accentuated. 
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Figure 19 – Collagen staining of osteopenic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
EXPRESSION OF OSTEOGENIC-RELATED MARKERS 
 
RT-PCR analysis showed that both experimental conditions – osteopenic control cultures 
and with doxycycline – expressed high levels of significant osteogenic markers. Results are 
shown in Graphic 11. 
At day 7, cultures with doxycycline expressed higher levels of ALP, Col I and OPN, 
comparing with the control culture. At day 14, control cultures expressed reduced levels of 
OPN and OC, while the expression of ALP, BMP-2, Col I and OPG was elevated. At the same 
time point, cultures with doxycycline expressed higher levels of these genes. 
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EXPRESSION OF ADIPOGENIC-RELATED MARKERS 
 
RT-PCR analysis of adipogenic markers is shown in Graphic 12. 
At day 7, the expression levels of CFD decreased in cultures with doxycycline. On the 
other hand, at day 14, in cultures with doxycycline the expression of CFD increased in 
comparison with the control culture. 
 
  
Graphic 11 – RT-PCR gene expression of ALP, BMP-2, Col I, OPG, OPN and OC, in osteopenic rat bone marrow-
derived cell cultures established at days 7 and 14, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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ESTABLISHMENT OF BONE MARROW-DERIVED OSTEOBLASTIC CULTURES 
FROM OSTEOPOROTIC ANIMALS 
 
In the third part of this study, the principal aim was to establish a bone marrow-derived 
osteoblastic culture from osteoporotic animals in two different conditions – in the absence and 
in the presence of doxycycline at 1 μg/ml. Cultures established in the absence of doxycycline 
were referred as ‘C osteoporotic’; and cultures with doxycycline were termed as ‘D1 
osteoporotic’. 
Cells were cultured in control medium and the first subcultures were evaluated for cell 
morphology, cell viability/proliferation and osteoblastic differentiation throughout the 14 days 
of culture time. 
 
 
  
Graphic 12 – RT-PCR gene expression of PPARγ, CFD and AP-2, in osteopenic rat bone marrow-derived cell 
cultures established at days 7 and 14, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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CELL PROLIFERATION 
 
The DNA content was the method used to assess the cell proliferation of the established 
cultures (Graphic 13). In the control culture from osteoporotic animals, cell proliferation 
increased till the tenth day of culture, being the increase from day 8 to day 10 very 
accentuated. Then cell proliferation decreased greatly at day 14. The culture with doxycycline 
didn’t have a similar behavior, increasing in a more regular way over the time of culture. The 
DNA values are lower in the doxycycline culture than in the control culture, except for the 
fourteenth day of culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METABOLIC ACTIVITY 
 
Metabolic activity was evaluated by the MTT assay (Graphic 14). Cultures established 
from osteoporotic animals without introduction of any osteogenic inducers presented an 
increasing from the first day till day 10 and then showed a slight decrease in the last day of 
culture. The time-course growth pattern of cultures with doxycycline was a little bit different – 
MTT reduction values increased over the 14 days of culture. 
 
Graphic 13 – Cell proliferation of osteoporotic rat bone marrow-derived cell cultures, established 
for 14 days, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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APOPTOSIS 
 
Apoptosis was assessed by the Caspase-3 assay and is represented in Graphic 15. The 
apoptosis is constant throughout the culture time and there are no significant differences 
between the two experimental conditions. 
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Graphic 14 – Metabolic activity of osteoporotic rat bone marrow-derived cell cultures, established 
for 14 days, in the absence and in the presence of doxycycline. 
Graphic 15 – Apoptosis of osteoporotic rat bone marrow-derived cell cultures, established for 14 
days, in the absence and in the presence of doxycycline. 
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CELL MORPHOLOGY 
 
CLSM was the method used for the assessment of cell morphology and the acquired 
images are shown in Figure 20. In control cultures, cells were elongated and the actin fibers 
were with an intense staining. Cell to cell contacts were established and, at day 8, an organized 
flattened sheet of continuous cell layers were verified. The cultures with doxycycline 
presented a similar cellular behavior. 
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Figure 20 – CLSM imaging of osteoporotic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
Cytoskeleton was stained in green and nucleus counterstained in red. A to C corresponds to control cultures, and D 
to F corresponds to cultures with doxycycline. Magnification 400x. 
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ALKALINE PHOSPHATASE ACTIVITY 
 
Results of ALP activity were normalized by total protein content and are show in Graphic 
16. In the control osteoporotic culture, ALP activity increased over the time of culture. The 
cultures established in the presence of doxycycline demonstrated a similar time-course growth 
pattern – increased ALP activity values from the first day till the last day of culture. Doxycycline 
culture showed higher ALP activity than the control culture during the entire culture time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALKALINE PHOSPHATASE STAINIG 
 
Images shown in Figure 21 are representative of ALP staining. At day 5 clusters of cells 
can be acknowledged, which start to grow and cover a vast majority of the culture plate in 
later time points, days 10 and 14. The staining intensity also increased over the time of culture, 
passing through a light brown in day 5 to a dark brown/black in days 10 and 14. There are no 
significant differences between the two experimental conditions. 
  
Graphic 16 – ALP activity of osteoporotic rat bone marrow-derived cell cultures, 
established for 14 days, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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Figure 21 – ALP staining of osteoporotic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
COLLAGEN STAINING 
 
Figure 22 is representative of collagen staining in osteoporotic cultures with and without 
doxycycline. At day 5 it’s visible the presence of nodular aggregates that increased and 
become more intense. The staining at day 5 is very light and it becomes darker from day 8 to 
day 10. At days 10 and 14 the pink is more intensive and the cell structure occupy almost the 
whole culture plate. The staining and organization pattern are similar in both experimental 
conditions.  
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Figure 22 – Collagen staining of osteoporotic rat bone marrow-derived cell cultures, established for 14 days, in the 
absence and in the presence of doxycycline. 
A to D corresponds to control cultures, and E to H corresponds to cultures with doxycycline. Magnification 100x. 
 
 
EXPRESSION OF OSTEOGENIC-RELATED MARKERS 
 
RT-PCR analysis showed that both experimental conditions – osteoporotic control 
cultures and with doxycycline – expressed high levels of significant osteogenic markers. Results 
are shown in Graphic 17. 
At day 7, cultures with doxycycline expressed higher levels of Col I, OPG, OPN and OC 
than the osteoporotic control culture. On the other hand, at the same time point, cultures with 
doxycycline expressed reduced levels of ALP and BMP-2 in comparison with control cultures. 
At day 14, the expression of osteogenic markers increased with addition of doxycycline. 
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EXPRESSION OF ADIPOGENIC-RELATED MARKERS 
 
RT-PCR analysis of adipogenic markers is shown in Graphic 18. 
At day 7, the expression levels of CFD decreased in cultures with doxycycline. At day 14, 
the expression of PPARγ increased, while the CFD expression decreased, in comparison with 
the control culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graphic 17 – RT-PCR gene expression of ALP, BMP-2, Col I, OPG, OPN and OC, in osteoporotic rat bone marrow-
derived cell cultures established at days 7 and 14, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
Graphic 18 – RT-PCR gene expression of PPARγ, CFD and AP-2, in osteoporotic rat bone marrow-derived cell 
cultures established at days 7 and 14, in the absence and in the presence of doxycycline. 
* – significantly different from control (p< 0.05). 
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V. DISCUSSION 
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Osteoporosis is a condition very current and increasingly common in the world population, 
and thus a matter of high concern and interest. There is a high predisposition to fractures that 
cause pain and disability and their occurrence is more common in women (4). An imbalance in 
the processes of bone formation and bone resorption may be the cause of this disease (49). 
Osteoporosis can be characterized by loss of bone mass and changes in microscopic 
architecture of the bone. As a result, bone becomes more brittle and fracture risk increases 
(31,32). It is known that bone has the capacity of self-regeneration; however, bone 
regeneration is a complex process not yet completely understood, especially when 
osteoporosis is present. 
Numerous investigations have addressed the bone healing and regeneration processes 
using animal models of osteoporosis. Rodent models have an extensive employment due to 
their availability, easy of manipulation, relative low cost and biological significance. 
 
In this work two animal models were established, the osteopenic and the osteoporotic rat. 
Osteopenia was established following the physiological development of the aging process. 
Animals with 48 weeks were used within this group. Microtomographic evaluation the 
proximal tibia revealed a discrete, yet significant reduction of the BV/TV, Tb N and Mean 
Density, supporting the state of osteopenia. Furthermore, osteoporosis was established with 
an ovariectomy surgical procedure and induced fast modifications within bone morphometric 
parameters. OVX animals, euthanized at 20 weeks of age, revealed a reduction in the BV/TV 
and Tb N of more than around 3 times. A significant reduction of the Mean Density was also 
attained. Verified differences, due to attained magnitude, corroborate the establishment of a 
model of the osteoporotic condition. In order to compare the developed models with a 
physiological control, sham animals – in which a sham ovariectomy procedure was conducted 
– were euthanized at 20 weeks of age. 
 
Following the establishment of the animal models, the in vitro protocol was divided in 
three parts, in which three metabolic conditions were evaluated. To do that, we established 
bone marrow-derived osteoblastic cultures from sham, osteopenic and osteoporotic animals, 
at the reported time points. 
A comparative approach allowed to identify some patterns in the cellular behavior of the 
cultures derived from the distinct metabolic conditions. Briefly, in which regards cell 
proliferation, the cultures established from osteopenic animals demonstrated a slower 
proliferation and the lowest values of DNA. The metabolic activity revealed a similar pattern in 
the three cultures, which reached the confluence at day 10 and decreased at day 14. However, 
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the cultures from osteopenic animals were the ones with lower MTT values during the culture 
time. Sham cultures were the ones that started with higher MTT values, having a less 
accentuated increase, while osteoporotic cultures started with lower values but reached 
similar ones of those obtained in the sham culture at day 10. In terms of functional activity, 
osteopenic cultures were the ones with lower ALP activity, followed by osteoporotic and sham 
cultures, which presented the higher ALP enzymatic activity. 
These results come in line with previous established research. A large body of literature 
indicates that age-related impaired bone formation is the principal pathogenic mechanism 
mediating age-related bone loss (90). Our model of osteopenia is essentially age-dependent 
and reported evidence converges to assist that the impaired bone formation results from age-
related decreased in osteoblast number and function, as consequences of multitude intrinsic 
senescence-related mechanisms (90). Essential mechanisms include an impairment of the cell 
proliferation, decline in the cellular lifespan, and the impairment of the differentiation, 
function, and response capability to endogenous and exogenous factors (91-93). Furthermore, 
genetic-related factors also seem to be of importance, and can be grouped into two defined 
groups: damage-related factors and maintenance (repair) factors. Disturbances in the balance 
between damage and maintenance factors increase the risk of cellular senescence and 
dysfunction (90). 
Furthermore, in the bone marrow microenvironment, both fat and bone tissue co-exist 
and several histomorphometric studies have demonstrated that the observed decrease in 
trabecular bone volume is correlated with an increased bone marrow adipocyte tissue volume, 
during the aging process. This consideration, described as ‘the inverse relationship between 
adipocyte and osteoblast differentiation’, was supported by experimental evidence in MSC 
cultures of animal models (94). More recent human studies revealed that the adipocyte-
forming capacity of MSC does not change with age and that no age-related change in the 
expression of mRNA levels of adipocyte and osteoblast differentiation markers was detected in 
humans (95). These later results come in line with the gene expression results, in which a 
similar level of expression of both osteogenic and adipogenic markers was verified in both 
sham and osteopenic-derived cultures. 
In which regards to the osteoporotic condition, the loss of bone mineral density is 
attributable to a pathological imbalance between bone resorption and bone formation during 
the remodeling process. Whereas the postmenopausal osteoporosis is mainly attributable to 
the increased bone resorbing activity of osteoclasts caused by estrogen deficiency, senile 
osteoporosis is attributed to inadequate osteoblastic function (96). A large number of 
experimental studies indicate that, in osteoporotic conditions, osteoblasts are characterized by 
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lower proliferation and defective function compared with normal osteoblasts. Related 
mechanisms might involve abnormalities of the IGF-I signaling system (97), a different 
production pattern of cytokines involved in the regulation of bone metabolism (98), which 
converge to occurrence of a different metabolic phenotype in osteoporotic osteoblasts and 
indicate the presence of reduced anabolic function (99). Furthermore, animal models and in 
vitro studies have demonstrated a disequilibrium in the RANK/RANKL/OPG system in 
osteoporotic conditions. A human in vitro study has further suggested that the up-regulation 
of RANKL on bone marrow cells is an important determinant of increased bone resorption 
induced by estrogen deficiency (55). 
Overall, within the established in vitro model of osteoblastic cultures derived from three 
distinct metabolic conditions, it was verified that the aging-related osteopenic condition was 
found to greater affect the functionality of cultured cells, sustaining a preponderant effect of 
the senescence process over the ovariectomy – osteoporotic condition. Despite this 
realization, microtomographic indexes were found to be more significantly affected in 
osteoporotic animals sustaining that the metabolic function/functional activity of bone 
marrow-derived osteoblasts might not be directly related to morphometric indexes of the 
bone tissue. 
 
Besides that, we aimed to assess the doxycycline effect in these three conditions. 
Tetracyclines are a well-characterized family of antibiotics that may have specific therapeutic 
value in the treatment of bone diseases, since they have great affinity for mineralized bone 
matrix (100). Besides that, they have been found to exert an extensive variety of catabolic 
actions over the metabolic balance of the bone tissue by modulating both osteoblastic and 
osteoclastic functions (101). Doxycycline is a representative of broad-spectrum tetracyclines 
antibiotics that is extensively used in medical and dental practice. These antimicrobial drugs 
revealed an overall positive effect on bone, being considered potential inductive agents for the 
management of the osteopenic and osteoporotic conditions (102). 
Knowing the ability of tetracyclines to improve the osteogenic function in a wide range of 
models, both in physiological and pathological conditions (like osteoporosis), the choice of 
using it was based on the possibility of enhancing the osteogenic potential of osteoblast 
precursor cells in the metabolic conditions above mentioned – sham, osteopenia and 
osteoporosis. Therefore, when accomplished the subculture, doxycycline (1 μg/ml) was added 
to the established cultures, in the absence of any osteogenic inducer. 
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In the first part of this study we established and characterized bone marrow derived 
osteoblastic cultures from sham animals. Were settled two conditions – control and with 
doxycycline at 1 μg/ml. The cells were then characterized assessing the cell proliferation, 
metabolic and functional activities. Cell proliferation was evaluated by the DNA content and 
the results showed an increased over the time of culture. The addition of doxycycline showed 
to induce the proliferation of cells. Metabolic activity, assessed by the MTT assay, increased in 
the first 10 days of culture and decreased at day 14, in the control cell culture. Culture with 
doxycycline presented a similar time-course growth pattern – metabolic activity increased till 
day 10, day where the confluence was reached, and decreased at fourteenth day. Comparing 
the two cultures, it’s visible that doxycycline stimulated metabolic activity in the first 8 days of 
culture, but from day 10 to day 14 the control culture showed higher MTT reduction values. A 
similar behavior is found in functional activity – ALP activity increased till day 10 and 
diminished at day 14. This activity is stimulated by doxycycline at days 8 and 10. Histochemical 
staining for ALP correlated the biochemical determination, revealing a high and increased stain 
intensity and nodular aggregation throughout the time of culture. The histochemical for 
collagen also showed an increase in staining in both cultures. The apoptosis, assessed by the 
Caspase-3 activity, was constant during the time of culture and it was not altered with the 
introduction of doxycycline. 
The RT-PCR analysis of osteogenic markers revealed that the expression level of ALP, BMP-
2, Col I, OPG and OPN was similar at day 7 and the addition of doxycycline stimulated the 
expression of these markers. At day 14, the expression level of ALP, BMP-2, Col I and OPG was 
almost the same, but OPN and OC were expressed in reduced levels. As expected, doxycycline 
addition enhanced the expression of ALP, such as the expression of OPN and OC. However, the 
expression levels of BMP-2, Col I and OPG slightly decreased. 
In terms of expression of adipogenic markers, at day 7, PPARγ and AP-2 were expressed at 
a similar level and the addition of doxycycline decreased their expression. CFD was expressed 
in higher levels at day 7 and its expression was enhanced with introduction of doxycycline. At 
day 14, PPARγ and AP-2 were the markers with higher levels of expression. However, at this 
time point, the addition of doxycycline reduced the expression of all the adipogenic markers. 
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In the second part of this study, the aim was to establish and characterize bone marrow-
derived osteoblastic cultures from osteopenic animals. Once again, were stated two conditions 
– control and with doxycycline to enhance osteogenic function – and cell proliferation, 
metabolic and functional activities were then assessed. Cell proliferation increased throughout 
the time of culture and it’s evident that the presence of doxycycline stimulated cell 
proliferation, especially in the last days of culture. In metabolic activity the cultures presented 
a different behavior, in both cultures the metabolic activity increased till day 10, day where 
confluence was reached, and decreased at day 14. However, the culture with doxycycline 
showed lower MTT values than the control culture. In terms of Caspase-3 activity, the 
apoptosis had a decline at day 10 but returned to normal values at day 14. There were no 
significant differences between the two experimental conditions. The ALP activity showed a 
similar behavior in both conditions, increasing over the time of culture. The addition of 
doxycycline enhanced the ALP activity in the eighth and tenth days of culture. These results 
were corroborated with histochemical data, in which it’s possible to see the increasing in 
nodular aggregates and stain intensity. Being ALP an important osteoblastic marker, the 
osteoblastic phenotype was maintained in the two conditions. Collagen staining revealed an 
increasing in the coloration with no evident differences between the two cultures. 
ALP is one of the most important genetic markers for osteoblasts being expressed during 
osteoblastic differentiation. The expression of ALP showed a slight increase from day 7 to day 
14 and, in both time points, it was intensified with the addiction of doxycycline. OPN, other 
marker for osteoblast differentiation, showed the higher levels of expression at day 7 in both 
conditions; however, this marker showed the lower expression levels in the control culture at 
day 14 and was enhanced with doxycycline. The expression of BMP-2, Col I and OPG didn’t 
show significant differences in the two conditions at day 5 but the expression of these markers 
increased at day 14 and it was stimulate with introduction of doxycycline. The expression of 
OC, often used as a marker for the bone formation process, didn’t show significant differences 
at day 5 in both conditions, but the addiction of doxycycline stimulated greatly its expression 
at day 14. In general, the expression of osteogenic markers increased with addition of 
doxycycline, being this other parameter that confirms that this antibiotic stimulates the 
differentiation of osteoblasts. 
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In terms of the expression of adipogenic markers, PPARγ, a marker expressed in 
adipocytes, showed reduced levels of expression at day 7 that increased at day 14 and, in both 
time points, its expression levels were enhanced by addition of doxycycline. CFD was the 
adipogenic marker that revealed a higher expression at day 5 being reduced with doxycycline. 
At day 14, the expression of CFD in control cultures was lower than at day 14 but it was 
stimulated when doxycycline was introduced. AP-2 expression increased with introduction of 
doxycycline in both experimental conditions. Despite the different levels of adipogenic 
expression, doxycycline stimulated the expression of all of the genes used. In terms of values, 
the levels of expression of adipogenic markers are similar to those obtained in osteogenic 
markers, so the established osteopenic culture had a propensity to the adipogenic 
differentiation alike the osteogenic one. 
 
In the third part of this work, we had the goal of establish and characterize bone marrow-
derived osteoblastic cultures from osteoporotic animals. The osteoblastic cells were cultured 
with and without doxycycline and cell proliferation, metabolic and functional activities were 
evaluated. Cell proliferation of the control culture increased from day 5 to day 10 and 
decreased at day 14. On tenth day of culture, control cells cultures reached confluence, and 
cell proliferation is inhibited by cell to cell contact what justify the decrease at the fourteenth 
day. Culture with doxycycline didn’t present this type of behavior, the proliferation rate 
increased throughout the whole time of culture, so doxycycline presented a slower cell 
proliferation rate and its peak was reached later, at day 14. Metabolic activity of control 
culture increased till day 10 of culture and decreased at day 14, while culture with doxycycline 
showed an increase over the 14 days of culture. Accordingly, doxycycline delays the metabolic 
activity and the cells achieve confluence later. There were no substantial differences between 
the two cultures in apoptosis, being the apoptosis values low in both experimental conditions, 
so doxycycline doesn’t interfere in the controlled cell death. In terms of functional activity, 
control culture revealed a regular increase in ALP throughout the time culture. The addition of 
doxycycline showed a stimulatory effect, increasing the activity of ALP since the first day of 
culture, being this outcome more marked at day 10. Histochemical results for ALP underpinned 
the biochemical data being visible the increase in staining intensity and number of clusters in 
both conditions. At day 10 it was also detectable a darker coloration in the doxycycline culture 
when compared with the control. The histochemical for collagen revealed an increasing in 
staining intensity for both cultures and no significant differences were visible. 
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In terms of the gene expression of osteogenic markers, ALP and BMP-2 had a similar level 
of expression at day 7 and then suffered a slight decrease when doxycycline was added. At day 
14, the expression of both markers increased but, while ALP revealed a decrease in the culture 
with doxycycline, the expression of BMP-2 was stimulated by doxycycline. Weren’t found 
significant differences in Col I expression at days 7 and 14, and it’s evident that doxycycline 
enhanced its expression in both time points. The expression level of OPG at day 7 was similar 
in both experimental conditions. At day 14, the OPG expression increased which was 
stimulated with addition of doxycycline. This pattern of expression wasn’t observable in OPN 
and OC expression; these two genes showed the highest level of expression at day 7 that was 
stimulated when doxycycline was introduced. However, at day 14 their expression was much 
reduced, but doxycycline revealed a stimulatory effect once again. 
The expression of adipogenic markers was really irregular and showed different results. At 
day 7 the expression levels of PPARγ and AP-2 were low, while CFD was expressed in elevated 
levels. The doxycycline had different effects in these markers, stimulating the expression of 
PPARγ and AP-2 and inhibiting the CFD expression. At day 14 the osteoporotic cells from the 
control culture expressed PPARγ, CFD and AP-2 at a similar level; however, the doxycycline 
enhanced the expression of the first one and decreased the expression of the other two 
markers. With these results we can see that the established osteoporotic culture didn’t have 
great propensity to differentiate into an adipogenic phonotype at day 7, but at day 14 the 
levels of expression were higher, so it’s possible that the adipogenic differentiation happens 
later in the culture time. 
 
The results obtained in this experimental work are in line with the evidences found in the 
literature about bone metabolism and pathology in animal models. In a mouse model used to 
simulate diabetic-induced osteopenia was verified that the pathological situation 
(characterized by decreased bone formation and not augmented bone resorption) was 
significantly ameliorated with tetracycline uptake (103). Bone regeneration in a dog model 
revealed that the administration of tetracycline induced a more regenerative healing and 
minimized crestal resorption, in comparison to control (104). Also in a dog model, the 
administration of doxycycline reduced the severity degree of osteoarthritis, with reduced 
levels of total collagenase activity and inhibition of the proliferation and hypertrophy of 
chondrocytes (105). These results were later confirmed in a double-blinded, randomized, 
placebo-controlled trial that reported a doxycycline-dependent reduction in the rate of joint 
space narrowing, in knees of obese women with established osteoarthritis (106). Studies with 
ovariectomized rats revealed that low dose of tetracycline administration increased bone 
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formation and mass levels (107). Tetracycline administration to squirrel monkeys, in a model 
of normal bone metabolism, increased the deposition of osteoid in the alveolar process by 
increasing the number of active osteoblasts (108). 
In human bone marrow-derived osteoblastic cells, doxycycline has increased significantly 
the number of active osteoblastic cells that provided a proportional amount of a normal 
mineralized ECM (109). This behavior was further confirmed when the human osteoblastic 
cultures were grown on the surface of two biomaterials for bone regeneration – HA and a 
glass-ceramic composite (110). A similar effect was found in human osteoblasts, in which 
doxycycline enhanced cell maturation and differentiation rather the process of proliferation 
itself (111). Recently, studies revealed that doxycycline at 1 μg/ml increase the OC, osteonectin 
and ALP expression in human periodontal ligament cells. Besides that, the increase in ALP 
expression was found to be more significant than the one induced by BMP-2 (112). 
Regarding to bone metabolism relevance, tetracyclines showed to have some effect in the 
modulation of the osteoclastogenic response. Recent studies found that doxycycline and 
minocycline (is also a broad-spectrum tetracyclines antibiotics) have the ability to inhibit the 
RANKL-induced osteoclastogenesis of precursor cells, but they didn’t show any effects on cell 
growth and phagocytic activity. In addition, the authors also reported the absence of effect on 
cell proliferation or differentiation in bone-forming osteoblast. Similarly, were perfomed some 
in vivo studies which revealed that the injection of tetracyclines into RANKL-injected mice and 
RANKL-transgenic mice suppressed the RANKL-mediated osteoclastogenesis process and 
promoted the concomitant appearance of CD11c+ cells (113). 
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Osteoporosis is a prevalent disease characterized by a low bone mass and changes in the 
microarchitecture of the bone tissue, which result in increased bone fragility and fracture risk. 
In this pathological condition, the new bone formation decreases and the bone regeneration 
process can be affected. This way, bone tissue engineering strategies require biomodulators to 
achieve a successful regeneration of the bone tissue and tetracyclines are a good example of 
this type of biomodulators. 
In this work, there were established bone marrow-derived cultures from sham, osteopenic 
and osteoporotic animals and it was assessed the effect of tetracycline in these three 
conditions. Cell cultures established from the sham group shown an increased cell proliferation 
in the presence of doxycycline. Doxycycline was also found to enhance metabolic activity and 
ALP expression of the established cultures. Doxycycline stimulated cell proliferation and ALP 
activity in cultures established from osteopenic animals. This stimulatory effect of doxycycline 
was corroborated by the high expression of osteogenic markers such as ALP, BMP-2, Col I, 
OPG, OPN and OC. In cultures established from osteoporotic animals, doxycycline showed a 
delay in cell proliferation and in metabolic activity; however, the expression of ALP was 
stimulated, what confirmed the maintenance of an osteoblastic cell-like phenotype. RT-PCR 
evaluation of significant osteogenic markers also revealed an enhancement with addition of 
doxycycline. 
The results presented in this study showed that doxycycline can be a suitable candidate to 
improve the osteogenic potential of osteoblast precursor cells in osteopenic and osteoporotic 
conditions. Therefore, these antimicrobial drugs can be useful in tissue engineering and have a 
potential biomedical application, being used in the treatment of osteoporosis 
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